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Abstract: The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015.
The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination
therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances
in tumor biology and immunology has led to the development of new targeted and immunotherapeutic
agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Im-
munotherapies in particular have emerged as highly successful approaches to treat patients with cancer
including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer,
and Hodgkin’s disease. Specifically, many clinical successes have been using checkpoint receptor blockade,
including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and
the programmed cell death-1 (PD-1) and its ligand PD-L1. Despite demonstrated successes, responses
to immunotherapy interventions occur only in a minority of patients. Attempts are being made to im-
prove responses to immunotherapy by developing biomarkers. Optimizing biomarkers for immunotherapy
could help properly select patients for treatment and help to monitor response, progression and resistance
that are critical challenges for the immuno-oncology (IO) field. Importantly, biomarkers could help to
design rational combination therapies. In addition, biomarkers may help to define mechanism of action
of different agents, dose selection and to sequence drug combinations. However, biomarkers and assays
development to guide cancer immunotherapy is highly challenging for several reasons: (i) multiplicity of
immunotherapy agents with different mechanisms of action including immunotherapies that target acti-
vating and inhibitory T cell receptors (e.g., CTLA-4, PD-1, etc.); adoptive T cell therapies that include
tissue infiltrating lymphocytes (TILs), chimeric antigen receptors (CARs), and T cell receptor (TCR)
modified T cells; (ii) tumor heterogeneity including changes in antigenic profiles over time and location in
individual patient; and (iii) a variety of immune-suppressive mechanisms in the tumor microenvironment
(TME) including T regulatory cells (Treg), myeloid derived suppressor cells (MDSC) and immunosup-
pressive cytokines. In addition, complex interaction of tumor-immune system further increases the level
of difficulties in the process of biomarkers development and their validation for clinical use. Recent clini-
cal trial results have highlighted the potential for combination therapies that include immunomodulating
agents such as anti-PD-1 and anti-CTLA-4. Agents targeting other immune inhibitory (e.g., Tim-3) or
immune stimulating (e.g., CD137) receptors on T cells and other approaches such as adoptive cell transfer
are tested for clinical efficacy in melanoma as well. These agents are also being tested in combination with
targeted therapies to improve upon shorter-term responses thus far seen with targeted therapy. Various
locoregional interventions that demonstrate promising results in treatment of advanced melanoma are also
integrated with immunotherapy agents and the combinations with cytotoxic chemotherapy and inhibitors
of angiogenesis are changing the evolving landscape of therapeutic options and are being evaluated to
prevent or delay resistance and to further improve survival rates for melanoma patients’ population. This
meeting’s specific focus was on advances in immunotherapy and combination therapy for melanoma. The
importance of understanding of melanoma genomic background for development of novel therapies and
biomarkers for clinical application to predict the treatment response was an integral part of the meet-
ing. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into
personalized-medicine approach for treatment of patients with melanoma across the entire spectrum of
disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across
different tumors represents a bridge to impact on prognosis and response to therapy in melanoma. We
also discussed the requirements for pre-analytical and analytical as well as clinical validation process as
applied to biomarkers for cancer immunotherapy. The concept of the fit-for-purpose marker validation
has been introduced to address the challenges and strategies for analytical and clinical validation design
for specific assays.
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Abstract 
The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. The four sessions at this 
meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immuno-
therapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has 
led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival 
(PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful 
approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carci-
noma (RCC), bladder cancer, and Hodgkin’s disease. Specifically, many clinical successes have been using checkpoint 
receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-
4) and the programmed cell death-1 (PD-1) and its ligand PD-L1. Despite demonstrated successes, responses to 
immunotherapy interventions occur only in a minority of patients. Attempts are being made to improve responses 
to immunotherapy by developing biomarkers. Optimizing biomarkers for immunotherapy could help properly select 
patients for treatment and help to monitor response, progression and resistance that are critical challenges for the 
immuno-oncology (IO) field. Importantly, biomarkers could help to design rational combination therapies. In addi-
tion, biomarkers may help to define mechanism of action of different agents, dose selection and to sequence drug 
combinations. However, biomarkers and assays development to guide cancer immunotherapy is highly challenging 
for several reasons: (i) multiplicity of immunotherapy agents with different mechanisms of action including immuno-
therapies that target activating and inhibitory T cell receptors (e.g., CTLA-4, PD-1, etc.); adoptive T cell therapies that 
include tissue infiltrating lymphocytes (TILs), chimeric antigen receptors (CARs), and T cell receptor (TCR) modified T 
cells; (ii) tumor heterogeneity including changes in antigenic profiles over time and location in individual patient; and 
(iii) a variety of immune-suppressive mechanisms in the tumor microenvironment (TME) including T regulatory cells 
(Treg), myeloid derived suppressor cells (MDSC) and immunosuppressive cytokines. In addition, complex interaction 
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Molecular and immune advances
The Cancer Genome Atlas (TCGA) identified four 
genetically defined subtypes of cutaneous melanoma: 
BRAF mutant, RAS mutant, NF1 mutant, and Triple 
Wild-Type. Mutations in each of the driver genes (BRAF, 
RAS, and NF1), contribute to deregulation of the mito-
gen activating protein kinase (MAPK/ERK) pathway, 
leading to uncontrolled cell growth. The most common 
subtype found was the BRAF subtype with 52% of cuta-
neous melanoma tumors harboring BRAF somatic muta-
tions. Additional frequently affected molecular pathways 
identified through the TCGA analysis include the PI3K/
AKT/mTOR (i.e., PTEN loss of function), cell cycle regu-
lators (i.e., CdDKN2a, CDK4, CCND1), P53 (i.e., Tp53, 
MDM2), and epigenetic regulation (i.e., ARID2a) path-
ways [1].
PTEN is a negative regulator of PI3K in the PI3K/AKT/
mTOR pathway. Complete loss of PTEN increases sign-
aling through the PI3K-AKT signaling pathway, which 
is commonly assessed by measuring levels of phospho-
rylated (activated) AKT. Loss of function of PTEN is 
a frequent event in melanoma, particularly in tumors 
with BRAF(V600) mutations. Complete loss of PTEN 
expression correlates with shorter overall survival (OS) 
in patients with stage IIIB/C melanoma. Interestingly, 
loss of PTEN did not correlate with shorter time to dis-
tant metastasis, but instead specifically correlated with 
an increased risk of melanoma brain metastasis (MBM) 
[2]. In addition, analysis of tumors from patients that 
underwent resection of both brain and non-CNS metas-
tases demonstrated that the MBMs were characterized 
by increased activation of the PI3K/AKT/mTOR pathway 
[3].
Gene expression profiling and synthetic lethality 
siRNAs screens in human melanoma cell lines impli-
cated Oxidative Phosphorylation (OxPhos) in resist-
ance to BRAF and MEK inhibitors [4]. The High OxPhos 
phenotype correlated with the expression of Peroxisome 
proliferator-activated receptor gamma coactivator 1-α 
(PGC1α), which is a transcriptional co-activator and a 
central inducer of mitochondrial biogenesis. Analysis of 
tumor biopsies from patients with acquired resistance to 
BRAF inhibitors demonstrated that ~50% of tumors had 
increased PGC1α expression compared to expression 
levels prior to treatment. Similarly, ~50% of human mel-
anoma cell lines with de novo or acquired resistance to 
MAPK pathway inhibitors exhibited a High OxPhos phe-
notype. The High OxPhos cell lines were all sensitive to 
combined inhibition of mTORC1/2 and the MAPK path-
way, whereas Low OxPhos cell lines were not. Focused 
studies demonstrated mTORC1/2 inhibition caused cyto-
plasmic sequestration of Microphthalmia-Associated 
Transcription Factor (MITF) and subsequent decreased 
expression of MITF-regulated genes, including PGC1-α. 
Experiments using human melanoma xenografts dem-
onstrated that both mTORC1/2 inhibitors and a direct 
OxPhos inhibitor could inhibit the growth of High 
OxPhos, MAPKi-resistant melanomas in vivo.
Activation of the PI3K/AKT/mTOR pathway by loss 
of PTEN was also shown to promote resistance to T 
cell mediated cell killing in vitro and in vivo [5]. Loss of 
PTEN correlated with decreased CD8 T cell infiltrates in 
of tumor-immune system further increases the level of difficulties in the process of biomarkers development and 
their validation for clinical use. Recent clinical trial results have highlighted the potential for combination therapies 
that include immunomodulating agents such as anti-PD-1 and anti-CTLA-4. Agents targeting other immune inhibi-
tory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors on T cells and other approaches such as adoptive cell 
transfer are tested for clinical efficacy in melanoma as well. These agents are also being tested in combination with 
targeted therapies to improve upon shorter-term responses thus far seen with targeted therapy. Various locoregional 
interventions that demonstrate promising results in treatment of advanced melanoma are also integrated with immu-
notherapy agents and the combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing 
the evolving landscape of therapeutic options and are being evaluated to prevent or delay resistance and to further 
improve survival rates for melanoma patients’ population. This meeting’s specific focus was on advances in immuno-
therapy and combination therapy for melanoma. The importance of understanding of melanoma genomic back-
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was an integral part of the meeting. The overall emphasis on biomarkers supports novel concepts toward integrating 
biomarkers into personalized-medicine approach for treatment of patients with melanoma across the entire spectrum 
of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different 
tumors represents a bridge to impact on prognosis and response to therapy in melanoma. We also discussed the 
requirements for pre-analytical and analytical as well as clinical validation process as applied to biomarkers for cancer 
immunotherapy. The concept of the fit-for-purpose marker validation has been introduced to address the challenges 
and strategies for analytical and clinical validation design for specific assays.
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clinical specimens, as well as increased expression of sev-
eral immunosuppressive cytokines. Further, melanoma 
patients with loss of PTEN expression had inferior clini-
cal responses to anti-PD-1 therapy compared to patients 
with retained PTEN expression. While pan-PI3K inhibi-
tors inhibited immune cell viability and function, a PI3K-
β-isoform-selective inhibitor did not significantly affect 
immune function and induced synergy with checkpoint 
inhibitors in vivo.
These findings reinforce the significance of the PI3K/
AKT/mTOR pathway in melanoma. OXPhos and mTOR 
are potential biomarkers to select patients for treatment 
with mTORi and the direct inhibitors of OXPhos as a 
new personalized therapeutic strategy. In addition, the 
findings support the rationale to combine PI3K/AKT/
mTOR inhibitors with immunotherapy. Further investi-
gations in this area, however, will need to balance anti-
tumor effects, toxicities, and immune effects to fully 
realize clinical benefit, potentially through the use of iso-
form-selective inhibitors and/or novel dosing strategies.
The characterization of the mutational landscape of 
melanoma using the exome sequencing of 108 sun-
exposed melanomas [6] at Yale University demonstrated 
the presence of genomic aberrations:( i) oncogenic muta-
tions in RAC1, a GTPase member of the RAS superfam-
ily, with RAC1P295 mutation affecting 4–7% of patients; 
(ii) recurrent mutations in PPP6C gene encoding serine/
threonine-protein phosphatase 6 catalytic subunit regu-
lating activity of the mitotic Aurora kinase A oncogene. 
At least 16 Aurora kinase inhibitors are in clinical studies, 
two of which (MLN8237/alisertib and GSK1070916A) 
are investigated in melanoma; and (iii) inactivating muta-
tions in the neurofibromatosis type 1 (NF1) tumor sup-
pressor gene known to negatively regulate RAS signaling. 
NF1 mutations occur in 30–45% of human melanomas 
that are BRAF/RAS WT, suggesting that NF1 may be a 
driver mutation in this subset, which, until now, was not 
amenable to targeted therapy approaches.
A recently carried out exome sequencing screen of 213 
sun-exposed melanomas at Yale confirmed these find-
ings and showed that NF1 is the third most frequently 
mutated driver gene in melanoma after BRAF and NRAS 
oncogenes [7]. In this cohort, inactivating NF1 muta-
tions (mostly nonsense mutations, bi-allelic with loss 
of the WT allele) were found in 12% of patients, result-
ing in low NF1 protein expression and NRAS activa-
tion. Consequently, some NF1-mutant melanomas cell 
lines are sensitive to treatment with MEK inhibitors. 
NF1-mutant melanomas harbored concurrent MAPK 
pathway mutations, such as mutations in RASA2, includ-
ing a recurrent mutation at position R511C observed in 
three NF1-mutant melanoma samples. The RASA2R511C 
gene mutation that increases phospho-ERK (pERK) 
activation was recently found in a patient with Noonan 
syndrome, a known developmental syndrome defined as 
RASopathy. Rasopathies are caused by germline muta-
tions in genes encoding transducers and modulator pro-
teins participating in the RAS-MAPK signaling pathway 
including RASA2, PTPN11, SOS1, RAF1 (Noonan syn-
drome), protein tyrosine phosphatase, non-receptor type 
11, PTPN11 (Leopard syndrome), and SPRED1 (Legius 
syndrome). There is clinical evidence for additive effect of 
NF1 and PTPN11 germline mutations that lead to severe/
lethal forms of Noonan syndrome and neurofibroma-
tosis [8]. Somatic mutations in PTPN11 have been also 
observed in several types of leukemia [9]. In total, 60% 
of melanomas with mutated NF1 also have mutations in 
PTPN11, SOS1, RASA2, SPRED1 and RAF1. The major-
ity of gene mutations in NF1-mutant melanomas are the 
very same documented disease-causing mutations as 
seen in RASopathy patients.
The emerging mutational landscape in melanoma, 
which includes genes from several intracellular pathways, 
will enable patient targeted gene sequencing for deter-
mining melanoma diagnosis, prognosis and treatment 
options [10]. Targeted gene sequencing can distinguish 
benign from malignant melanocytic lesions, provides 
information regarding mutational evolution of in melano-
cytic lesion [11], assess drug sensitivity and resistance. 
The beneficial effects of BRAF inhibitors in melanoma 
patients bearing BRAF V600 mutations is well estab-
lished, but the main issue remains the development of 
drug resistance, which is responsible for disease relapse 
within months after treatment. In most cases BRAFi 
resistant melanoma bear mutations reactivating MAPK 
pathway, e.g., MEK1 mutations and BRAF or KRAS 
amplification [12]. The observed frequent reactivation 
of MEK pathway in BRAFi resistant tumors led to the 
development of BRAFi +  MEKi combination therapies, 
which improve survival but are unable to prevent disease 
relapse [13].
Progress in understanding of the evolution of resist-
ance to targeted therapies in melanoma has been made 
in the recent years [14]. Two types of acquired BRAF 
inhibitor resistance have been proposed in this study: one 
caused by genetic variants such as double BRAF/NRAS 
mutant melanoma and another caused by a melanoma 
dramatically over-expressing a wild type receptor tyros-
ine kinase such as Platelet-derived growth factor recep-
tor beta (PDGFRB). The consequences of these genetic 
versus non-genetic mechanisms are quite different. The 
genetic mechanism leads to reactivation or supra-baseline 
hyper-activation of the MAPK pathway and maintains 
MAPK-addiction. On the other hand, the non-genetic 
mechanism, while it still maintains tonically active MAPK 
signaling, has turned on alternative or MAPK-redundant 
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growth and survival. Accordingly, addition of a MEK 
inhibitor would only re-sensitize the genetically driven 
resistant cells to the BRAF inhibitor since they’re still 
addicted to the MAPK pathway. MAPK-addicted can be 
distinguished from redundant resistance based on at sev-
eral features. In MAPK-redundant resistance, phospho-
ERK (pERK) levels and mutant BRAF signature output 
are still responsive to the BRAF inhibitor. Also, MAPK-
redundant resistance is associated with transcriptome re-
programming and a mesenchymal morphologic switch.
As more and more resistant cell lines and tumors from 
patients are analyzed, it became clear that, while genetic 
or sometime apparently non-genetic lesions (mutant 
BRAF alternative splicing which creates a N-terminally 
truncated BRAF) that hyper-activate the MAPK pathway 
may be different, they all render the resistant cells sensi-
tive to further MAPK pathway suppression. From stud-
ies that compare patient-derived resistant tumors to their 
patient-matched baseline tumors, it has become clear 
that combination therapy with BRAF-MEK inhibitors has 
not exhausted the reservoir of rare genetic variants capa-
ble of supra-baseline MAPK hyper-activation [15]. Two 
examples of these unusual genetic configurations can be 
postulated. One is what we termed gene ultra-amplifica-
tion selectively affecting mutant BRAF, resulting in back-
to-back dimerization with CRAF. The other is concurrent 
BRAF and MEK mutations, resulting in a face-to-face 
interaction akin to the BRAF association with kinase sup-
pressor of RAS (KSR) scaffolding protein. One conse-
quence of a recalibrated MAPK signalsome is a striking 
phenotype of drug addiction where double-drug with-
drawal led to slow-cycling (quiescent) or loss of viability.
Not all genetic lesions causing acquired resist-
ance hit the MAPK pathway; a significant minority hit 
the PI3K-PTEN-AKT pathway. These genetic vari-
ants can in theory potentiate an adaptive response that 
occurs early on treatment and stem from both cancer 
cell-autonomous and paracrine mechanisms [16, 17]. 
However, genetic alterations did not seem adequate to 
explain the acquired resistant phenotype in patients [18]. 
Beyond mutant BRAF amplification and RAS (NRAS, 
KRAS) alterations, the other genetic mechanisms were 
not highly recurrent, and on the whole many cases of 
acquired resistance were unaccounted for by any specific 
genetic lesion. Deeper profiling and integrated analysis 
of the exome with the transcriptome and methylome 
across 48 pairwise before-and-after tumor comparisons 
demonstrated patterns of non-genomic and immune 
evolution of melanoma acquiring MAPKi resistance. 
Specifically, highly recurrent transcriptomic and cor-
related methylomic changes that supported alterations 
in a wide variety of cancer phenotypes were uncovered. 
Some of these changes (such as reduction in apoptotic 
sensitivity due to LEF1 and YAP1 alterations) are tumor 
cell-intrinsic, as supported by parallel functional analysis 
of MAPKi-resistant cell lines. Importantly, a significant 
fraction of MAPKi resistant tumors lose CD8 T infiltrat-
ing cells, suggesting loss of responsiveness to salvage 
anti-PD-1 therapy.
Thus, the stage is set to understand the origin of this 
omic-wide reprogramming, tumor heterogeneity, and 
co-evolution of the intra-tumoral immune microenviron-
ment. To do so, it will be important to dissect alterations 
that take place early during MAPKi therapy, when the 
tumors are regressing and staying “dormant” or “quies-
cent” during the response period. From analysis of such 
tumors as well as cell lines and mouse models, the het-
erogeneous responses within tumor populations, their 
interactions, and temporal alterations before frank clini-
cal relapse (within microscopic foci of resistance) can 
be appreciated. These insights might rationalize upfront 
combinations that truly restrict the bottleneck of mela-
noma evolution on MAPK targeted therapy. Thus, bioin-
formatics and system biology approaches are needed to 
integrate multi -omics databases to generate models for 
clinical melanoma management [19].
TCGA analysis also identified three clusters based on 
a transcriptomic classification of melanoma specimens. 
Discriminatory mRNA transcript profile enriched for 
immune gene expression associated with lymphocyte 
infiltrate based on pathology review and high lympho-
cyte specific protein tyrosine kinase (LCK) expression, 
was associated with improved patient survival and 
was named “immune” cluster [1]. A significant num-
ber of genes overexpressed in this subclass were associ-
ated with immune cell subsets (T cells, B cells, and NK 
cells), immune signaling molecules, co-stimulatory and 
co-inhibitory immune checkpoint proteins, cytokines, 
chemokines, and corresponding receptors. Importantly 
immune infiltration is statistically correlated with more 
favorable prognosis irrespective of genomic subtype 
designated by BRAF, RAS (N/H/K), NF1 mutations, and 
Triple-WT. The question of whether specific mutated 
melanoma antigens are responsible for differences in the 
degree of tumor infiltration by lymphocytes is an area of 
active investigation.
“Keratin” cluster represents biologically distinct mela-
noma subtype with adverse prognosis was characterized 
by high expression of genes associated with keratins, 
pigmentation, and epithelium, as well as genes associ-
ated with neuronal development or other organ-specific 
embryologic development and in addition included kal-
likreins and other epidermal genes. The ‘‘MITF-low’’ 
cluster was characterized by low expression of genes 
associated with pigmentation and epithelial expression 
including several MITF target genes and genes involved 
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in immunomodulation, adhesion, migration, and extra-
cellular matrix.
Also, global transcriptome also demonstrates immu-
nomodulatory effects on melanoma in patients treated 
with sorafenib and dacarbazine. Upregulation of inter-
feron (IFN)-stimulated immune response genes consist-
ent with proinflammatory environment including IFNγ, 
T-cell infiltration and immune activation correlated with 
metabolic response assessed by PET-CT during sorafenib 
and dacarbazine therapy in patients with advanced mela-
noma. Induction of IFNγ stimulated genes correlating 
with increased level of serum IFNγ was found to be pre-
dictive of better clinical outcome [20].
Epigenetic regulation is also known to control tumor 
progression affecting a number of pathways (such as 
immune responsiveness, chemoresistance, stem-like 
behavior or apoptosis). Increased activity of the epi-
genetic modifier histone-lysine N-methyltransferase 
enzyme (EZH2) has been associated with different can-
cers and central role of EZH2 in promoting growth and 
metastasis of cutaneous melanoma have been found. 
EZH2 inactivation in melanoma-bearing mice stabilizes 
the disease through inhibition of growth and abolish-
ment of metastases formation.
Comparably, in human melanoma cells, EZH2 inactiva-
tion impairs proliferation and invasiveness, accompanied 
by re-expression of tumour suppressor gene and increase 
patient survival. [21]. Whereas, increased expression of 
EZH2 in human melanoma was found to be associated 
with poor survival.
Adaptive mechanisms of drug resistance can also be 
linked to activation of receptor tyrosine kinases such as 
EGFR, IGF1R, PDGFR, AXL, EPHA2 [22]. Hyperactiva-
tion of ERBB3 receptor through phosporylation has been 
observed as an early feedback survival loop both in vitro 
and in  vivo in response to RAF/MEK inhibition. This 
activation can be abrogated by anti-ERBB3 antibodies 
preventing the establishment of resistance to BRAF/MEK 
inhibitors in melanomas [23]. The feedback survival loop 
is promoted by increased autocrine production of EGFR 
ligand neuregulin, whose increased level of gene expres-
sion has been observed after BRAFi treatment in several 
cell lines and its secretion occurs shortly after melanoma 
cell exposure to BRAFi [24].
The combination of two monoclonal antibodies 
(mAbs) called A3 and A4 against two distinct epitopes 
of the extracellular domain of ERBB3 abrogates vemu-
rafenib-induced ERBB3 activation, enhances inhi-
bition of melanoma cells growth, and restores drug 
sensitivity to vemurafenib in BRAFi-resistant mela-
noma cells. It also reduced tumor relapse in an in vivo 
xenograft model when combined with vemurafenib and 
trametinib.
An alternative mechanism of resistance to targeted 
therapy involves miRNA expression. As miRNAs are 
master regulators of gene expression and miRNA dereg-
ulation impacts on several cellular processes such as 
cancer development, metastasis, invasion, migration 
and progression. Recently miRNA have emerged as a 
molecular regulator in the development and progression 
of melanoma. Study in melanoma cells led to identifica-
tion of miR-579-3p targeting BRAF and MDM2 that con-
trols growth and migration processes. Lower miR-579-3p 
level is observed in melanoma as compared to nevus, and 
higher levels correlate with good prognosis in melanoma 
patients. There are also accumulating data that miRNAs 
are involved in drug resistance and may be a biomarker 
to predict response to therapy. miR-579-3p was found 
to be downregulated in melanomas from patients who 
developed resistance to targeted therapies such as BRAFi 
and its level is inversely correlated with expression of tar-
get genes [25].
Investigating differentially expressed miRNAs in pre- 
and post-treatment melanoma biopsies may identify 
critical pathways hijacked in therapy-resistant tumors. 
Analysis of the miRNA expression profiles in BRAF-
resistant tumors may enhance understanding of the bio-
chemical mechanisms of resistance to targeted therapies.
CD8+ T cell-inflamed melanoma shows signs of 
increased immune suppressive mechanisms and anti-
PD-1 therapy appears to be preferentially effective in 
T cell-inflamed tumors [26]. However, the underlying 
molecular mechanisms that can explain the absence of a 
T cell response in the majority of patients are not defined.
Exome sequencing and gene expression profiling of 
melanoma biopsies revealed activation of β-catenin in 
a 49% of non-T cell-infiltrated tumors. Using an induc-
ible autochthonous mouse melanoma model (BRAFV600E/
PTEN−/−  ±  CAT-STA+; BP and BPC), a causal effect 
between tumor-intrinsic active β-catenin signaling and T 
cell exclusion was demonstrated [27]. Mechanistic studies 
revealed a lack of T cell priming against tumor-associated 
antigens in the context of β-catenin-expressing tumors. 
In-depth analysis indicated that absence of T cells was 
caused by defective recruitment of CD8α+ and CD103+ 
dermal dendritic cells (DC) into the tumor site, due to 
repressed expression of the chemokine CCL4. Further-
more, the knockdown of ATF3, a transcriptional repres-
sor of CCL4, restores CCL4 expression in β-catenin+ 
tumor cells. Tumors expressing active β-catenin were 
resistant to therapy with anti-CTLA-4/anti-PD-L1 anti-
bodies, mimicking the phenotype observed in humans 
[27]. The absence of CD103+ dendritic cells led to 
defective early T cell priming and absence of systemic 
immunity. However, whether tumor-intrinsic β-catenin 
signaling is responsible for mediating tumor resistance 
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even after an anti-tumor T cell response is established 
remains elusive. To test this notion, the spontaneously 
rejected tumor cell line MC57.SIY, which is known to 
induce an immunologic memory mediating immune 
surveillance was used. Following rejection of MC57.SIY 
in BP-SIY and BPC-SIY hosts autochthonous tumors 
were induced. Although the primary SIY-specific CD8+ 
T cell response and the induced memory response were 
comparable between both tumor models, tumor protec-
tion was observed only against BP-SIY tumors, whereas 
it no protection BPC-SIY tumors. This increased tumor 
control in BP-SIY mice was accompanied by strong T 
cell infiltration and a boosted memory response. These 
results suggest that tumor-intrinsic β-catenin signaling 
might also be responsible for the observed exclusion of 
migrating effector T cells into the tumor site.
Taken together, these data provide strong evidence that 
up-regulation of β-catenin in tumor cells is a very potent 
mechanism of immune evasion against not only a pri-
mary immune response, but also against an immunologic 
memory. Moreover, tumor-intrinsic β-catenin activation 
likely mediates resistance not only to checkpoint block-
ade therapy but also to T cell adoptive transfer. Future 
studies will focus on therapeutic solutions targeting the 
activated β-catenin pathway with the intention to allow 
inflammation into this subset of tumors. In conclu-
sion, tumor-intrinsic β-catenin signaling mediates lack 
of T cell infiltration and resistance towards checkpoint 
inhibition.
As one of the immune-based approach, adoptive 
cell therapy (ATC) has become an increasingly attrac-
tive modality for the treatment of patients with cancer. 
Endogenous population of tumor reactive T cell infiltrate 
is often absent in many solid tumor malignancies and 
transfer of such T cells to patients may lead to improved 
therapy. The augmentation of endogenous immune 
response may be obtained through autologous tumor-
infiltrating lymphocytes (TILs), engineered T cells such 
as T cell receptor (TCR) modified T cells or chimeric 
antigen modified T cells (CAR), or circulating T cell ther-
apy [28, 29]. Endogenous T cells (ETC) are derived from 
peripheral blood or tumor infiltrating lymphocytes as a 
source of effector cells for adoptive cell therapy.
Autologous effector enriched TILs were demonstrated 
as effective treatment for melanoma and potentially other 
tumors, although the antigen specificity in this infu-
sion product has not been established. Disadvantages of 
TILs treatments include selection bias. TCR modified 
T cells and CARs provide antigen specificity by target-
ing specific peptide in the context of HLA or cell surface 
expressed antigen recognized by the antibody (Ab) rec-
ognition domain, respectively. Both TCR modified T cells 
and CAR products have shown efficacy in treatment of 
leukemia and other malignancies including melanoma. 
Disadvantages of using these cellular products are seri-
ous toxicities and safety/regulatory problems. ETC shows 
significant advantages having naturally occurring “self-
selected” affinity. Moreover, peripheral blood as a source 
is very accessible and associated with low comorbidity. 
ETC is unfortunately time consuming, labor-intensive 
and technically challenging.
Rare population of tumor-reactive T cells present in 
the peripheral blood at frequencies as low as 1:100,000 
or 0.001%, can be expanded in vitro up to >80% specific 
T cells in a population of 106 cells. Preparation time can 
be significantly reduced by using clinical grade peptide-
MHC-multimer-based sorting of antigen specific T cells. 
Strategies to enhance in  vivo persistence of transferred 
T cells can lead to improved antitumor efficacy [28, 
30–32]. However, the extrinsic (patient conditioning) 
and intrinsic factors (effector cells) contributing to long-
term in vivo persistence are not well-defined. As a means 
to enhance persistence of infused T cells in vivo and to 
limit toxicity, lymphodepletion using cyclophosphamide 
alone can be administered as conditioning before infus-
ing expanded peripheral blood mononuclear cell-derived, 
antigen-specific CD8+ cytotoxic T-lymphocyte (CTL) 
clones. In addition, IL-2 to build a better environment 
and priming with IL-21 in  vivo generates CTL clones 
with prolonged in vivo survival. Adoptive T cell therapy 
using ETC represents feasible, effective and safe modal-
ity. ETC therapy can be applied to treat patients with 
melanoma and non-melanoma solid tumor malignancies. 
Modulation of intrinsic features of T cells that enhances 
in vivo persistence and extrinsic immunomodulation has 
potential to improve tumor immunorespose.
In vivo tracking revealed that the conditioning regimen 
provided a favorable milieu that enabled CTL prolifera-
tion early after transfer and localization to nonvascu-
lar compartments, such as skin and lymph nodes. CTL 
clones in the infusion product were characterized by an 
effector memory phenotype and CTL that persisted long 
term acquired phenotypic and/or functional qualities of 
central memory type CTLs in vivo [28, 33].
CTLA-4 is one of the checkpoint receptors expressed 
on T cells that provides inhibitory signals, establishing a 
negative feedback loop for T cell activation. The negative 
regulation of the immune response maintains peripheral 
tolerance to self-antigens and prevents damage to normal 
tissue. Blocking CTLA-4 may sustain the activation and 
proliferation of tumor-specific T cells, thus permitting 
the development of an effective tumor-specific immune 
response.
In a phase I/II trial of adoptive T cell therapy in combi-
nation with immune checkpoint blockade (anti-CTLA-4) 
in metastatic melanoma patients led to establishment of 
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long-lived central memory T-cells. Evidence of epitope 
spreading was observed in patients with tumor regres-
sion/stable disease [28, 34].
Combination therapies
Some tumors escape immune surveillance by upregulat-
ing a number of immunosuppressive pathways to inhibit 
the activity of tumor specific T cells. Tumor immuno-
therapy that targets T cells immunosuppressive mecha-
nisms to unleash pre-existing anti-tumor immune 
response (e.g., immune checkpoints CTLA-4 and PD-1 
or its receptor PD-L1) has shown success in some tumors 
[35]. But for the majority of tumors with limited numbers 
or no tumor infiltrating T cells additional interventions 
are needed to generate this immune response. Radiother-
apy can be considered a good partner for immunotherapy 
because it is able not only to kill cancer cells but also to 
modify the tumor microenvironment, thus changing the 
immune system interaction with cancer potentially con-
verting a lymphocyte-poor tumor in a lymphocyte-rich 
one [36].
In support of this concept, the combination of local 
radiotherapy (RT) with CTLA-4 blockade was proven 
to be effective in a mouse model of breast cancer refrac-
tory to anti-CTLA-4 alone [37] and to drive an oligo-
clonal expansion of CD8+ TILs [38]. Non-ablative, 
hypo-fractionated RT (6 Gy × 5 or 8 Gy × 3) regimens 
were shown to be effective in inducing anti-tumor immu-
nity and abscopal effects, i.e., responses in non-irradi-
ated tumors, in combination with anti-CTLA-4 [39]. 
The preclinical studies have been recently validated in 
a prospective phase II trial testing the combination of 
RT and ipilimumab in patients with metastatic NSCLC 
(NCT02221739), a disease poorly responsive to ipili-
mumab alone. Responses (CR + PR) were seen in 33% of 
the patients who completed treatment and 18% based on 
intent-to-treat [40].
Ongoing studies are aimed at improving RT-induced 
in  situ vaccination. Generation of anti-tumor T cells at 
the irradiated tumor site is dependent on the balance of 
positive and negative signals that pre-exist or are induced 
by RT itself. Clearly, RT alone is seldom capable of induc-
ing T cell-mediated rejection of aggressive poorly immu-
nogenic tumors. One of the negative signals generated by 
RT is transforming growth factor (TGF)β. Activation of 
latent TGFβ by radiation-induced reactive oxygen species 
(ROS) hinders the activation of tumor-infiltrating den-
dritic cells (DC) and the priming of anti-tumor T cells. 
In this setting, TGFβ blockade showed a therapeutic 
synergy with radiation. Induced resistance in the tumor 
microenvironment with upregulation of PD-1 ligands 
limited responses, and PD-1 blockade was in fact able to 
extend survival of mice treated with the combination of 
radiation and TGFβ blockade and to delay tumor recur-
rence. Studies are ongoing to understand the mecha-
nisms of tumor recurrence. Data suggests that TGFβ 
neutralization results in an increase in intratumoral 
Treg, and that another TGFβ family member, activin A, 
s responsible for this effect [41]. Combined TGFβ and 
activin A blockade reduced Treg and increased tumor-
specific CD8 T cell responses, resulting in reduced recur-
rence rates. On the other hand, high dose radiotherapy 
leads to more release of ATP by dying cancer cells, which 
provides an activation signal to dendritic cells [42]. How-
ever, ATP can be rapidly converted to adenosine, which 
is immune-suppressive. This offers another potential tar-
get for intervention: blockade of adenosine generation 
improved recruitment and maturation of dendritic cells 
and tumor response to stereotactic body radiation ther-
apy (SBRT) [43].
PI3K-AKT pathway inhibitors were found to selectively 
target T regulatory cell (Treg) CD25(+) FoxP3(+) with 
minimal effect on conventional T cells (Tconv). These 
results clearly show selective in vitro inhibition of activa-
tion (as represented by a decrease in downstream sign-
aling) and proliferation of Treg in comparison to Tconv 
when treated with different AKT and PI3K inhibitors. 
This effect has been observed in both human and murine 
CD4 T cells [44]. Furthermore, it has been shown that 
PI3K-AKT inhibition enhances tumor antigen-specific 
vaccine efficacy and synergistically enhances anti-tumor 
responses [44]. In particular, AKT inhibition by MK-2206 
enhances the anti-tumor therapeutic effect of tumor-spe-
cific vaccine; the PI3K inhibitor Wortmannin differen-
tially affects proliferation of human Treg and Tconv cells. 
Similar results have been shown by inhibiting all class IA 
PI3K isoforms with the pan PI3K inhibitor GDC-0941. 
This observation suggests that Treg targeted therapies 
selectively reprogram Treg and represent an approach to 
circumvent a major element of immune suppression in 
patients with cancer.
A number of anti-tumor antibody-based therapies are 
aimed at direct killing of tumor cells or tumor microenvi-
ronment components including: (i) oncogenic receptors 
(Her2/neu, EGFR); (ii) non-oncogenic receptors (CD47), 
(iii) lineage specific molecules (CD20); (iv) tumor micro-
environment (VEGFR, B7-H series); and (v) tumor spe-
cific antigens.
Anti-HER2/neu antibodies reduce tumor burden 
through blocking the HER2 oncogenic pathway and also 
by Fc receptor (FcR) mediated antibody-dependent cell-
mediated cytotoxicity (ADCC). The therapeutic effect 
of anti-HER2/neu depends on natural killer (NK) cells, 
as depletion of NK cells significantly reduced efficacy of 
the treatment in mice. Antibodies have demonstrated 
an impact on immune response and tumor control in 
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various xenografted tumor models. The involvement 
of effector T cells for Ab-mediated tumor regression is 
also essential for tumor control in immunocompetent 
and syngeneic host [45]. This process depends on type I 
and II IFN and Myeloid differentiation primary response 
gene 88 (MyD88) [46]. MYD88 gene encodes a cytosolic 
adapter protein that plays a central role in the innate and 
adaptive immune response. This protein functions as an 
essential signal transducer in the interleukin-1 and toll-
like receptor signaling pathways and these pathways reg-
ulate that activation of numerous proinflammatory genes 
[47].
CD47 also known as integrin associated protein (IAP) 
is a transmembrane protein that in humans is encoded 
by the CD47 gene that is highly expressed on stem 
cells, including tumor stem cells. CD47 is involved in a 
range of cellular processes, including apoptosis, prolif-
eration, adhesion, and migration. CD47 serves as the 
ligand for signal regulatory protein alpha (SIRPa), which 
is expressed on phagocytic cells including macrophages 
and dendritic cells, that when activated initiates a signal 
transduction cascade resulting in inhibition of phagocy-
tosis. Considering that survival of tumor cells depends 
on the balance between “eat me” and “do not eat me” 
signaling, the question is whether anti-CD47 can be a 
candidate for targeting with therapeutic mAbs blocking 
a phagocytic inhibitory signal and inducing apoptosis. 
Anti CD47 antibodies were able to greatly reduce tumor 
burden and extend survival of human leukemia and in 
immunodeficient NSG mouse model [48].
The effect of anti-CD47 was also demonstrated to 
be based on CD8 T cells and its therapeutic effect 
depends on type I IFN responses [49]. However, neither 
MyD88 nor TIR-domain-containing adapter-inducing 
interferon-β (TRIF), that are two major downstream 
pathway members for IFN production are essential for 
anti-CD47-mediated tumor control. Thus, improved 
cytotoxic CD8+ T cells priming and increased DC cross-
priming are the major mechanisms underlying the thera-
peutic effect of anti-CD47 Ab, the latter requiring type 
I IFN pathway. The fact that T cells demonstrate anti-
tumor cytotoxic activity as a result of CD47-blocking 
antibody therapy could have important clinical implica-
tions. Anti-CD47 antibody—mediated phagocytosis of 
cancer by macrophages can initiate an antitumor T-cell 
immune response. Noteworthy, anti-CD47 antibody 
treatment not only enables macrophage phagocytosis of 
cancer, but also fosters the activation of tumor specific 
lymphocytes recognizing mutant proteins. Moreover, 
anti-CD47 Ab-mediated type I IFN induction by host 
DC that depends on activation of the stimulator of inter-
feron genes (STING) pathway leads to adaptive immune 
responses against tumors. As a therapeutic approach, 
intratumoral injection of STING agonists has demon-
strated profound therapeutic effects in multiple mouse 
tumor models, including melanoma, colon, breast, 
prostate, and fibrosarcoma. Better characterization of 
the STING pathway in human tumor recognition, and 
the development of new pharmacologic approaches to 
engage this pathway within the tumor microenvironment 
in patients, are important areas for clinical investigations. 
The experimental data suggests that anti-CD47 mAbs 
could be useful for monotherapy or as a component of 
combination treatment strategy for cancer treatment.
A critical checkpoint regulating the efficacy of T-cell-
based cancer immunotherapy that correlate with 
tumor T cell infiltrate can be accumulation of multiple 
chemokine receptors on effector T cells and chemokine 
ligands within the tumor site [50]. Indeed, increased 
levels of chemokine receptors on T cells were shown 
to increase anti-tumor response to PD-1 therapy [51] 
whereas reduced chemokine expression by tumor cells 
increase resistance [27]. Chemokine targeting strategies 
further offer promise in combination with other immu-
notherapies that rescue CD8+ T cell function.
LIGHT [(homologous to Lymphotoxin (LT), inducible 
expression, competes with herpes simplex virus (HSV) 
glycoprotein D for HSV entry mediator (HVEM), a 
receptor expressed on T lymphocytes)] is a TNF family 
member that interacts with lymphotoxin receptor (LTR)3 
and herpesvirus entry mediator (HVEM) expressed on 
stromal cells and T cells, respectively, and functions in 
T-cell responses. LIGHT systems also plays an important 
role in regulating expression of genes crucial for innate 
and adaptive defenses to pathogens and may contribute 
to immune tolerance in control of autoimmune diseases. 
LIGHT exhibits potent, CD28-independent costimula-
tory activity for T cell priming and expansion leading to 
enhanced T cell immunity against tumors by increasing 
tumor T cell infiltration and/or increased autoimmunity 
[52]. Targeting EGFR+ with anti-EGFR-LIGHT fusion 
protein in the tumor environment induces lymphotoxin 
beta receptor (LTβR)-associated chemokines and adhe-
sion molecules that attract and prime naive T cells lead-
ing to the rejection of established, highly progressive 
tumors in mice [50]. It raises the possibility that tumor 
can be targeted with LIGHT to generate more CTL to 
convert TME into inflamed phenotype.
It is generally assumed that molecules have to be 
expressed on plasma cell membrane in order to be rec-
ognized by the corresponding antibodies in viable cells. 
This assumption has excluded the use of intracellular 
molecules (such as chaperons, transcription factors, 
signaling transduction components) as potential targets 
of antibody-based immunotherapy for the treatment of 
malignant diseases. This dogma has been challenged, 
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since there is growing evidence that intracellular mole-
cules may migrate to the plasma cell membrane in malig-
nant cells. By panning a human phage display antibody 
library with a cultured human melanoma cell line we 
have isolated the single chain Fv(scFv) W9 which recog-
nizes an extracellular epitope of the intracellular chaper-
one glucose-regulated protein of 94,000 daltons which is 
a member of the heat shock protein 90 family (Grp94). 
This molecule, which is a member of the heat shock pro-
tein 90 family plays an important role in the biology of 
malignant cells because of its asssociation with compo-
nents of signaling pathways involved in cell proliferation, 
survival and migration [53]. The mAb W9 defined Grp94 
epitope is expressed on various types of malignant cells 
including melanoma. In different types of cancer, the 
epitope is expressed not only on differentiated cancer 
cells, but also on cancer initiating cells (CICs). The mAb 
W9 defined Grp94 epitope is upregulated on BRAFV600E 
melanoma cells upon treatment with BRAF inhibitors, 
and with chemotherapeutic agents. Furthermore the 
mAb W9 defined Grp94 epitope has a restricted distribu-
tion in normal tissues.
Therefore, Grp94 represents an attractive target for 
antibody-based immunotherapy of various types of solid 
tumors. The in  vitro and in  vivo anti-tumor activity of 
mAb W9 was investigated in a malignant melanoma 
model. The results indicate that mAb W9 inhibits the 
growth of melanoma cells. The antibody induces apop-
tosis as well as inhibits several signaling pathways (e.g., 
ERK, AKT and FAK). The anti-tumor activity of mAb W9 
is enhanced by the small molecule LDE225, an inhibitor 
of the sonic hedgehog homolog (SHH) pathway. Further-
more, mAb W9 delays the development of BRAF inhibi-
tor resistance in melanoma cells with mutant BRAF [54]. 
Lastly, mAb W9 induces the regression of experimental 
lung metastasis established in immunodeficient mice by 
intravenous injection of melanoma M21 cells. These data 
suggest that intracellular tumor antigens may be a useful 
source of targets for antibody-based immunotherapy of 
melanoma and other types of solid tumor and could be 
part of combination strategies with immunotherapeutic 
agents [55].
Intralesional therapy is a promising approach in mela-
noma treatment; especially for cutaneous metastases 
of metastatic melanoma that constitute a major clinical 
problem and that are accessible to injection in a high per-
centage of patients. The aim of this strategy is not only 
local control of melanoma, but potentially developing a 
systemic effect by stimulating an immune response after 
tumor injection.
A variety of oncolytic viruses are being tested in clini-
cal trials including adenovirus, vaccinia, herpes, reovirus, 
Seneca Valley virus and coxsackievirus [56]. Locoregional 
therapies include oncolytic viruses such as Talimogene 
laherparepvec, Newcastle disease virus (NDV), Cox-
sackie virus A21, HF10-oncolytic HSV1 and Reovirus, 
and non-viral based therapies (PV-10/Rose Bengal diso-
dium) demonstrated efficacy in patients with tumors with 
specific mutations or wild type tumors. Many questions, 
such as whether the combination of oncolytic viruses will 
provide synergy with other immunotherapy interventions 
and whether synergy might be a drug specific or spe-
cific for class of immunotherapy interventions remains 
to be tested. Considering that immune-active microen-
vironment and type I IFN transcriptional signature are 
associated with clinical benefit from immunotherapies, 
strategies targeting type I IFN pathway may sufficiently 
sensitize tumors to immune checkpoint blockade.
NDV has a potential as anti-cancer agent because it 
readily infects the majority of cancer cells because of 
ubiquitous expression of the viral receptor (containing 
sialic acid) and it is strong inducer of type I interferon 
and dendritic cells maturation. Clinical trials with sys-
temically-administered NDV in humans demonstrated 
safety and durable clinical benefit in different cancer 
types. The durability of the clinical benefit suggested the 
strong immune component responsible for the treatment 
efficacy. Furthermore, NDV infection in animal model 
upregulated MHC and co-stimulatory molecules on the 
surface of tumor cells and delayed distant B16-F10 tumor 
growth, although only few complete regressions were 
observed. On the contrary, combination therapy of NDV 
transfection and CTLA-4 blockade lead to rejection of 
the locally administered with the virus and distant B16-
F10 tumors and long-term survival in mice. In addition, 
the treatment induced inflammatory responses in dis-
tant tumors. Anti-tumor response of NDV and CTLA-4 
blockage combination therapy is dependent on CD8 T 
cells, NK cells, and type I and II interferons [57].
Another unanswered question is whether there is a role 
for oncolytic virus therapies in patients who fail check-
point inhibitors treatment. Coxsackievirus A21 (CVA21) 
is a naturally occurring Picornavirus, which CVA21 
displays potent oncolytic activity in both in  vitro can-
cer cells cultures and in vivo xenografts in mouse mod-
els of human cancers which exhibit high level of surface 
ICAM-1 expression. CVA21 rapidly replicates, rupturing 
the cells to release progeny virus particles and tumour 
antigens. Progeny virus continues the cycle by infecting 
and lysis of new cells, whereas tumor antigens activate 
the immune response [58]. CAV21 has shown an over-
all response rate of 26% and a disease control rate of 37% 
[59]. A phase 2 clinical study in humans demonstrated 
immune responses in injected lesions, non-injected vis-
ceral lesions and in distant non-injected visceral lesions. 
This strategy is tested as a rescue strategy to reconstitute 
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the immune response within the tumor microenvinment 
(TME) in lesions resistant to immune checkpoint block-
ade [60].
The main intralesional agent currently in phase III trials 
is Talimogene laherparepvec (T-VEC) that is a HSV-1-de-
rived oncolytic virus that has both a local effect (tumor 
cell lysis) and, to a lesser degree, a systemic effect (tumor-
specific immune response) [61–68] T-VEC kills injected 
and non-injected A20 tumors in mice and induces pro-
tection against re-challenge [65]. In clinical trials, it has 
shown good safety profile and a durable response rate is 
(16%). For now, the use of T-VEC monotherapy appears 
to be limited to unresectable Stage III patients who are 
poor candidates for other therapies, or are refractory to 
other available therapies. In a phase 3 melanoma clinical 
study, T-VEC monotherapy demonstrated a significantly 
higher durable response rate (DRR, ≥6 mos response) 
versus GM-CSF. Current and upcoming trials will focus 
on finding the right virus and/or the right combination in 
the right population.
Combining T-VEC that promotes release of tumor-
derived antigens with an immune checkpoint inhibitor 
that improves T cell responses such as ipilimumab signifi-
cantly enhances efficacy of the combination as compared 
to either therapy alone. The phase 1b portion of a phase 
1b/2 combination study (NCT01740297) completed 
enrollment and met its primary objective with no dose 
limiting toxicities and objective response rate (ORR) of 
56% [69]. Also the combination of another oncolytic virus 
Pelareorep with anti-PD-1 MAb resulted in prolonged 
survival of mice injected with melanoma [70]. PV-10 is an 
investigational new drug containing a proprietary inject-
able formulation of Rose Bengal disodium (10% RB), a 
water-soluble xanthene dye currently in use in a topical 
ophthalmic diagnostic. PV-10 is designed for intralesional 
administration into solid tumors with an established 
safety history and prolonged retention in tumors. Pre-
clinical data of combination of intralesional injection of 
PV-10 with anti-PD-1 are also promising [71]. PV-10 is 
able to selectively accumulate in lysosomes of cancer cells 
triggering the acute cytolysis mediated by lysosomes. 
Phase II results with this agent have shown promising 
results with both local and systemic effect [72]. Interest-
ing results were also obtained in phase II trials with intra-
tumoral electroporation (EP) of the plasmid containing 
IL-12 gene (IT-pIL12-EP) as well as coxsackievirus A21 
(CVA21). The transfection of plasmid DNA-encoded 
IL-12 using leads to IL-12 expression at tumor site. IL-12 
initiates local pro-inflammatory processes and a systemic 
anti-tumor immune responses. Patients with advanced 
melanoma, treated with pIL-12 monotherapy have ben-
efited from a complete (14%) or partial response (17%), 
while the disease remained stable in 17% of patients and 
52% of patients had a progressive disease (52%).
In conclusion, intralesional approaches may be appli-
cable in melanoma treatment thanks to their local activ-
ity and the ability to trigger a systemic immune effect. 
Combination of locoregional therapy using oncolytic 
viruses with systemic immunotherapy such as checkpoint 
therapy appears to be safe and multiple agents and com-
binations are already in clinic or are in pre- and clinical 
development. Also, expanding the definition of “injecta-
ble lesion” to liver, deep lymph nodes and other locations 
would increase the efficacy of such therapies. However, 
further clinical studies and biomarkers are needed for 
optimal selection of patients for treatment with these 
agents to combine with other immunotherapy interven-
tions and to improve the outcome of such strategies.
Immune checkpoint blockade with agents such as ipili-
mumab, pembrolizumab, and nivolumab has dramati-
cally changed the outlook for patients with metastatic 
melanoma. Several studies have investigated the combi-
nation of various checkpoint blocking antibodies such as 
the combination of ipilimumab and nivolumab and the 
combination of ipilimumab and pembrolizumab. Ques-
tions remain about how to best combine or sequence 
these agents.
In a phase 2 study testing the combination of 
nivolumab +  ipilimumab versus ipilimumab as first-line 
treatment for patients with advanced melanoma, the 
combination of nivolumab and ipilimumab compared 
to ipilimumab alone demonstrated a higher objective 
response rate by RECIST 1.1 (Response rate: 61 versus 
11%, respectively) and progression free survival [73]. In 
the phase 3 study testing nivolumab +  ipilimumab ver-
sus nivolumab versus ipilimumab, the combination of 
nivolumab + ipilimumab had the highest numeric overall 
response rate and progression free survival. While these 
efficacy results seem to favor combination immuno-
therapy, one must consider the higher rate of side effects 
with combination immunotherapy (approximately 55% of 
grade 3/4 immune-related adverse events). Fortunately, 
most adverse events resolve with immunosuppressant 
medications, and discontinuing immunotherapy due to 
side effects does not appear to affect efficacy of immuno-
therapy as 67.5% of patients who discontinued the com-
bination due to side effects developed a response [74, 75].
The overall survival benefits of the combination com-
pared to single agent PD-1 are not yet known. Nonethe-
less, the long-term overall survival rates in the phase I 
study of the combination of nivolumab + ipilimumab are 
impressive with 68% of patients alive at 3-years. The most 
important question, however, is whether there will be an 
overall survival advantage of the combination upfront 
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versus single agent PD-1 first-line with ipilimumab (or 
the combination) as second-line therapy. Overall sur-
vival data from the phase 3 checkmate 067 study will be 
critical and determining the rate of cross-over to other 
immune checkpoint blocking antibodies in patients ini-
tially treated with single agent PD-1 and ipilimumab will 
be critical in this analysis.
Ideally there would be a biomarker to select the combi-
nation for patients who are most likely to benefit. Unfor-
tunately, no biomarker, including PD-L1, is yet ready to 
be used for selecting patients for combination immu-
notherapy versus single agent PD-1 or ipilimumab. This 
remains a highly active area of research.
Locoregional interventions can markedly improve 
overall survival in stage IV melanoma, can contribute 
to palliative care to improve quality of life or to decrease 
symptoms as well as it can be combined with other 
therapy approaches including immunotherapy or tar-
get therapy. Numerous technical advances in diagnostic 
methodologies e.g., intraoperative ultrasound imaging 
(IOUS), magnetic resonance imaging (MRI), positron 
emission tomography (PET) and PET-computed tomog-
raphy (PET/CT) provide 3-D tools for better diagno-
sis, staging and monitoring of the treatment of cancer 
including surgery.
Despite the major advances offered by new systemic 
therapies, surgery of stage IV melanoma remains an 
important therapeutic tool that can be used to rapidly 
and safely resolve localized disease. The rational for sur-
gical resection as first option in stage IV melanoma is 
based on several factors. Single lesions are best treated 
by surgery while studies have that shown complete 
resection is possible in 25% of stage IV patients (M1a 
through M1c inclusive) [76]. The surgical procedure has 
acceptable morbidity and mortality and is associated 
with favorable survival rates [77]. Several prognostic 
factors for surgery in metastatic melanoma have been 
identified. In particular, patients who have limited sites 
of metastatic disease, prolonged disease-free survival 
and a tumor-volume doubling time of >60 days may be 
amenable to surgical resection. It is also important to 
consider whether the lesion can be completely resected. 
Complete surgical excision of limited metastatic dis-
ease can result in prolonged progression-free survival 
(PFS) in carefully selected patients. Surgery for distant 
metastatic melanoma, however, is rarely curative since 
the majority of patients with distant metastases have 
widespread micrometastatic disease even if clinical and 
imaging criteria suggest limited spread. Large tumor 
masses are difficult to eradicate with systemic therapy 
alone and surgery in combination with novel immuno- 
and targeted therapies can potentially improve clini-
cal outcomes and/or patients’ quality of life. Indeed, 
surgery should be offered to reduce the target of sub-
sequent adjuvant medical treatment whenever pos-
sible. Thus, reduction of the tumor mass which can be 
obtained with surgery is important in combination with 
immunotherapy.
For example, overall survival for patients with distant 
metastases (M1a) recurrence treated with surgery and 
with or without systemic medical therapy (SMT) ver-
sus SMT alone was retrospectively compared in the first 
Multicenter Selective Lymphadenectomy Trial (MSLT-
I). Although all patients who underwent surgery had 
favorable survival (versus SMT alone), those with M1a 
metastases did particularly well. These patients had a 
median survival of greater than 60 months with surgery 
with or without SMT versus 12.4  months with SMT 
alone. These outcomes are superior to those on many 
patients with stage III metastases [77].
Surgery may also have an important role in combina-
tion with immunotherapy. Indeed, the removal of lesions 
that may be resistant to treatment with ipilimumab may 
improve outcomes for some patients. Pathological eval-
uation of the excised tissue is important to assess the 
presence of immune-infiltrate. In several cases, analysis 
of the excised tissue has revealed the presence of a dif-
fuse immune infiltration which correlated with the out-
come of these patients [78]. Also, surgery might be used 
as adjuvant, in combination with targeted therapy agents 
such as vemurafenib [79]. Thus, reduction of the tumor 
mass which can be obtained with surgery is important in 
combination with immunotherapy.
Surgery is very useful in well selected patients with 
stage IV melanoma and is associated with good outcomes 
and, in particular, combined modality approaches are 
likely to be most successful. Overall patients’ selection 
is paramount in order to identify patients most likely to 
benefit from surgery. Furthermore, clinical and trans-
lational studies are required to determine optimal com-
binations and treatment algorithms, but it appears that 
surgery should continue to play a prominent role.
News on immunotherapy
Adjuvant therapies can have a fundamental role in 
improving the survival of melanoma patients diagnosed 
at earlier operable stages but continue to be at a high-risk 
of death from melanoma relapse (AJCC stages IIB-III). 
Three major meta-analysis studies of all randomized con-
trolled trials (RCTs) of IFNα have supported its impact 
on relapse free survival (RFS) and overall survival (OS) of 
these patients [80]. Therefore, IFNα has been validated as 
a reference treatment in RCTs investigating new thera-
peutic agents for the adjuvant treatment of the high-risk 
population [81]. Positive results in terms of RFS were also 
achieved with adjuvant PEG IFNα2b administration in 
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stage III patients, where the modest RFS benefit seen was 
still significant at 7.6 years of median follow up [82].
The results of a preplanned interim analysis of the phase 
III adjuvant bevacizumab study in patients with high risk 
melanoma at (AVAST-M) trial were reported by Corrie 
et  al. [83]. This trial tested adjuvant bevacizumab versus 
observation in stage II/III resected melanoma patients 
(N = 1343). At a median follow-up of 25 months, overall 
survival and distant metastasis-free survival were similar 
among treatment arms and an improvement in the disease 
free interval (DFI) was observed (HR: 0.83; 95% CI 0.70–
0.98; p = 0.03). Longer follow-up is needed to better assess 
the modest DFI benefit seen and to evaluate the effect on 
the primary endpoint of overall survival at 5 years.
Neoadjuvant therapy has improved the outcome of 
patients with multiple different solid tumors, includ-
ing head and neck, breast, bladder, esophageal, and rec-
tal cancers [84–87]. Benefits include improvements in 
survival, surgical resectability, local control, and organ 
preservation. Other advantages of neoadjuvant therapy 
are the ability to evaluate the clinical and pathologic 
responses and the potential to identify immunologic and 
histologic correlates of tumor response. Access to tumor 
tissue before and after neoadjuvant therapy also may 
allow a better understanding of the antitumor mecha-
nisms of action that may enable more selective applica-
tion of therapeutic agents to those patients who are more 
likely to benefit.
Patients with locoregionally advanced but surgi-
cally operable melanoma continue to carry a high risk 
of relapse and death despite the best available standard 
management approaches. Neoadjuvant studies target-
ing this patient population tested chemotherapy with 
temozolomide and biochemotherapy (BCT), in which 
BCT demonstrated high tumor response rates but was 
eventually abandoned with the failure of BCT to deliver 
survival benefits in randomized trials of metastatic dis-
ease. Smaller neoadjuvant immunotherapy studies with 
IFNα and ipilimumab have yielded promising clinical 
activity and important mechanistic insights and bio-
marker findings. Newer targeted and immunotherapeutic 
agents and combinations currently are being translated 
into the neoadjuvant setting at an accelerated pace and 
carry significant clinical promise. In drug development, 
the neoadjuvant approach allows access to blood and 
tumor tissue before and after initiation of systemic ther-
apy, which allows for the conduct of novel mechanistic 
and biomarker studies in the circulation and the tumor 
microenvironment. Such studies may guide drug devel-
opment and allow for the discovery of predictive bio-
markers selected on the basis of their capacity to classify 
patients according to the degree of benefit from treat-
ment or the risk for significant toxicity.
Neoadjuvant ipilimumab was tested in locoregion-
ally advanced melanoma to evaluate safety and to define 
markers of activity and toxicity in the blood and tumor 
of patients at baseline and early on-treatment times 
[88]. Patients were treated with ipilimumab (10  mg/kg 
intravenously every 3  weeks for two doses) that brack-
eted surgery. Tumor and blood samples were obtained 
at baseline and at the definitive surgery time. Thirty-
five patients were enrolled; stages IIIB (3 patients; N2b), 
IIIC (32 patients; N2c, N3), and IV (two patients). The 
worst toxicities included grade 3 diarrhea/colitis (five 
patients; 14%), hepatitis (two patients; 6%), rash (one 
patient; 3%), and elevated lipase (three patients; 9%). The 
median follow-up was 19  months. Among 33 evaluable 
patients, the preoperative radiologic assessment by PET-
CT scans at 6–8 weeks after the initiation of ipilimumab 
revealed that three patients (9%) had objective responses 
(two patients, complete response; one patient, partial 
response). Twenty-one patients (64%) had stable disease, 
and eight patients (24%) experienced disease progres-
sion identified with PET-CT. [18F]-fludeoxyglucose PET/
CT parameters at baseline (T0) and at the first scan after 
two doses of ipilimumab (T1) were unable to predict the 
risk of recurrence after surgery (at the significance level 
of 0.05). The number of lesions at T1 showed a trend 
towards predicting a higher chance of disease recurrence 
(p = 0.06). The median RFS was 11 months (95% CI, 6.2–
19.2  months). Biomarker and mechanistic data nested 
within this study have supported the immunotherapeutic 
predictive value of the proinflammatory tumor microen-
vironment as measured by mRNA expression and CD8 
T cell density at the tumor invasive margin [88]. Other 
studies have supported a role for the TH17 pathway in 
mediating immune related colitis after treatment with 
ipilimumab [89]. Ongoing studies are testing the neo-
adjuvant therapeutic value ipilimumab in combination 
with IFNα (NCT01608594), pembrolizumab in combina-
tion with IFNα (NCT02339324) and the combination of 
ipilimumab-nivolumab as compared to nivolumab alone 
(NCT02736123).
Among other ongoing targeted neoadjuvant combina-
tion studies are trials with targeted therapy agents vemu-
rafenib/cobimetinib (NCT02303951, NCT02036086) and 
dabrafenib/trametinib (NCT01972347, NCT02231775). 
However, resistance ultimately develops in the majority 
of patients with metastatic disease, and several resistance 
mechanisms have been well characterized. Future stud-
ies optimizing MAPK pathway inhibition (targeting ERK 
and CDK4/6 as monotherapy and in combinations) and 
combinations that target alternate pathways implicated 
in mediating resistance (e.g., phosphoinositide 3-kinase 
[PI3K] and AKT), may take advantage of the neoadjuvant 
approach. Combination studies with immunotherapy 
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(including IFN, IL-2, anti-CTLA4, and anti–PD-1/PD-1 
ligand [PD-L1]) that are underway in patients with meta-
static disease also may be transitioned into the neoadju-
vant setting, supported by the hypothesis that the high 
response rates seen with BRAF/MEK inhibitors can be 
transformed into high durable response rates with immu-
notherapy [90, 91].
Other approaches for neoadjuvant therapy are intral-
esional approaches described earlier that have been 
shown to be relatively safe and well tolerated, with evi-
dence of local and potential bystander/distant antitumor 
clinical activity that appears to be most promising with 
T-VEC at this time. This approach may provide a neoad-
juvant therapeutic platform that can be combined with 
other immune-activating agents, including cytokines and 
checkpoint inhibitors. Combination studies of T-VEC 
with anti-CTLA4 and anti–PD-1 antibodies are under-
way in metastatic disease, and at least one neoadjuvant 
study with T-VEC monotherapy is planned in resectable 
regionally advanced melanoma (NCT02211131).
In conclusion, neoadjuvant therapy has the potential 
to improve the outcomes—including survival, surgical 
resectability, local control, and organ preservation—of 
patients with locoregionally advanced melanoma. Other 
advantages are the ability to evaluate the clinical and 
pathologic responses and the potential to identify immu-
nologic and histologic correlates of tumor response. 
Access to tumor tissue before and after neoadjuvant ther-
apy may allow a better understanding of the antitumor 
mechanisms of action that may enable more selective 
application of therapeutic agents to those patients who 
are more likely to benefit. Neoadjuvant immunotherapy 
with HDI and ipilimumab have yielded several important 
findings, and multiple studies involving newer immuno-
therapeutic and targeted agents and combinations are 
underway. Neoadjuvant therapy in melanoma continues 
to be investigational and should only be pursued in the 
context of a clinical trial [92].
The anti-CTLA-4 ipilimumab is an example of long-
term survival benefits with the use of immunooncol-
ogy compounds. Anti-CTLA-4 has shown to improve 
survival in melanoma patients and also to improve the 
long-term survival rate [93, 94]. Indeed, a median OS of 
11.4  months and a OS of 22% at 3  years were reported 
[94]. The EORTC18071 study is a phase III trial com-
pares adjuvant ipilimumab versus placebo after complete 
resection of high-risk stage III melanoma [95]. Patients 
with a single metastases in a sentinel node (SN) with a 
diameter <1  mm were excluded from this trial because 
of their excellent prognosis and very low relapse rate as 
recommended by the Rotterdam Criteria for tumor load 
in the SN [96–98]. Ipilimumab treatment was shown to 
improve relapse-free survival (RFS) significantly, with a 
hazard ration (HR) 0.74 (p < 0.0001) and to increase RFS 
rates at 2 and 3  years by 8 and 12% respectively, com-
pared to placebo [99]. Adjuvant ipilimumab treatment 
was approved in 2015 by the FDA. With ipilimumab 
adjuvant therapy a benefit was seen across all subgroups. 
Patients with positive SN and patients with ulcerated pri-
mary lesions derived the biggest benefit from adjuvant 
ipilimumab. Thus the beneficial effect of ipilimumab is 
broader than with adjuvant IFN therapy as ulceration 
of the primary lesion is the overriding predictive fac-
tor of outcome with no benefit for non-ulcerated mela-
noma. This has been observed in the EORTC 18952 and 
18991 trials in both a mature and long term analyses [82, 
95, 100–102], in individual patient data meta-analyses 
(IPDMA) of EORTC trials [101] and individual patient 
data meta-analyses (IPDMA) of all 15 adjuvant trials 
reported thus far [103]. The safety profile of adjuvant use 
of ipilimumab at 10 mg/Kg was generally consistent with 
that observed in advanced melanoma, although the inci-
dence of some immune-related adverse events (irAEs) 
(e.g., endocrinopathies) was higher in this study. Most 
patients came off treatment with ipilimumab after 4–5 
doses because of irAE and 5 patients died of drug related 
causes [99].
Anti PD-1 agent nivolumab has been shown to improve 
overall survival and progression-free survival, as com-
pared with dacarbazine, in previously untreated patients 
who had metastatic melanoma and that was significant in 
patients without a BRAF mutation [104]. More recently 
it has been demonstrated that nivolumab is equally 
effective in BRAF wild type patients and BRAF mutant 
patients alike [105]. Treatment of patients with advanced 
melanoma with the anti-PD-1 antibodies pembrolizumab 
and nivolumab has been demonstrated to be superior 
than treatment with ipilimumab alone [74, 106]. Recently, 
the EORTC1325 study has been activated, comparing 
another anti-PD-1 agent pembrolizumab therapy for 
1  year versus placebo after complete resection of high-
risk stage III melanoma. The EORTC trial will reach full 
accrual Q2-3 in 2016. In the USA a trial comparing adju-
vant pembrolizumab versus high dose IFN therapy will 
be conducted. Moreover, and adjuvant trial comparing 
ipilimumab versus nivolumab in stage IIIB/C/resected 
stage IV has recently reached full accrual [107]. The pro-
file of anti-PD1 antibodies in terms of high response rates 
and low toxicity is ideal for adjuvant use and the outcome 
of the trials is eagerly awaited [108].
Multiple mechanisms of melanoma-induced immune 
escape contribute to the failure of the spontaneous or 
vaccine-induced immune T cell responses to promote 
tumor regression in humans. In particular, a number of 
inhibitory pathways play a critical role in impeding T cell 
responses to tumor antigens (TAs), including PD-1, T-cell 
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immunoglobulin and mucin-domain containing-3 (Tim-
3) receptor, B- and T-lymphocyte attenuator (BTLA) 
and T-cell immunoreceptor with Ig and ITIM domains 
(TIGIT). These inhibitory receptors (IRs) are expressed 
by TA-specific CD8+ T cells in the tumor microenviron-
ment (TME) while their respective ligands are expressed 
by antigen-presenting cells (APCs) and tumor cells. In 
patients with advanced melanoma, TA-specific CD8+ 
T cells present in the periphery and at tumor site co-
express multiple IRs [109]. Circulating TA-specific CD8+ 
T cells and CD8+ tumor-infiltrating lymphocytes (TILs) 
that co-express PD-1, BTLA, and Tim-3 exhibit different 
level of T cell dysfunction [110, 111]. However, dysfunc-
tional/exhausted CD8+ TILs are not totally inert and can 
exhibit cytolytic functions but are likely kept in check by 
the inhibitory pathways in the TME that can be released 
upon immune checkpoint blockade. Also, IRs can also 
be upregulated by activated T cells such as functional 
vaccine-induced CD8+ T cells in patients with advanced 
melanoma. In particular, PD-1 and Tim-3 regulate the 
expansion and function of vaccine-induced TA-specific 
CD8+ T cells, supporting combinatorial therapies with 
cancer vaccines and immune checkpoint blockade to 
increase the clinical efficacy of cancer vaccines [112].
Among IRs, TIGIT appears to represent an interest-
ing target for the next generation of immune checkpoint 
blockade for several reasons. First, it is highly expressed 
by the majority of CD8+ TILs together with PD-1. Sec-
ond, the TIGIT ligands, CD155/PVR, and CD112, are 
highly expressed in the TME by melanoma cells and APCs. 
Third, it has been shown that dual PD-1/TIGIT blockade 
augments the expansion and function of human TA-spe-
cific CD8+ T cells in  vitro and promotes tumor rejec-
tion in animal models [113]. Interestingly, CD8+ TILs 
in melanoma downregulate the costimulatory molecule 
CD226, which competes with TIGIT for binding to the 
same ligands CD155 and CD112. Therefore, in addition 
to the TIGIT-mediated T-cell intrinsic inhibitory effects, 
the downregulation of CD226 expression resulting in the 
imbalance of TIGIT/CD226 expression by CD8+ TILs, 
may contribute to decrease T cell responses to melanoma 
[109, 113]. These data support implementation of dual 
PD-1/TIGIT blockade in clinical trials to determine its 
capability to increase the clinical benefits of monotherapy 
with PD-1 inhibitors in patients with advanced melanoma.
Strategies aimed at changing the tumor microenviron-
ment (TME) include direct injection into tumor, check-
point inhibition and vaccine/adjuvants. Early phase 2 
trial data presented at the 2015 ASCO demonstrated 
by multi-spectral analysis that Coxsackievirus A21 
induces both immune cell infiltration and up-regulation 
of immune response genes in the micro-environment of 
melanoma lesions. Similarly, adoptive immunotherapy 
with PD-1-deficient CD4+ tumor-specific T cells has 
been shown to augment therapeutic efficacy of tumor-
specific CD8 T cells [114], presumably through an 
increase in infiltration and destruction of tumors.
Alternative approaches to change the TME include can-
cer vaccines. Short-lived proteins (SLiPs) and defective 
ribosomal products (DRiPs) are at the center of the MHC 
class I antigen processing pathway, linking immunosur-
veillance of viruses and tumors to mechanisms of special-
ized translation and cellular compartmentalization. Since 
SLiPs and DRiPs, are thought to represent the majority of 
epitopes presented by tumor cells and enable the immune 
system to rapidly detect alterations in cellular gene 
expression with great sensitivity [115], they represent a 
compelling choice for cancer vaccines. Methods to gen-
erate vaccines that contain SLiPs and DRiPs from cancer 
cells by inhibiting the proteasome and lysosomal degrada-
tion of resulting autophagic vesicles has been established. 
These vaccines have provided striking anti-cancer activ-
ity in a variety of preclinical animal models [116, 117]. 
Further, preliminary data suggests that the intranodal 
vaccination DRibbles+ CDN (cGAMP, STING Ligand) 
significantly augments the intratumoral CD8: FoxP3 ratio.
Recently, this approach was applied in clinical trials for 
patients with NSCLC and prostate cancer. DPV-001 is an 
off-the-shelf allogeneic DRibble vaccine developed from 
two human cancer cell lines (cGMP; adenocarcinoma 
and mixed histology (squamous/adeno)). The vaccine is 
composed of DC-targeted microvesicles containing natu-
ral agonists for TLR 2, 3, 4, 7 and 9, 15 DAMPs and more 
than 170 proteins overexpressed by the average NSCLC. 
Preliminary data from a phase II trial of cyclophospha-
mide with DPV-001 alone or with GM-CSF or imiquimod 
for adjuvant treatment of definitively treated stage IIIa or 
IIIb NSCLC showed that DPV-001 induced and boosted 
broad anti-cancer immunity in every patient [118]. This 
immunity was assessed by detection of IgG antibody 
responses using 9000 protein spotted arrays. Since devel-
opment of IgG antibodies requires antigen-specific CD4 
T cell help IgG responses can serve as a surrogate of CD4 
T cell immunity [119].
T cells engineered to express high affinity T cell 
receptors or chimeric antigen receptors (CAR) have 
been successful for treating cancer and hematologi-
cal malignancies. CD19- and CD22-CAR T cell therapy 
is currently being used children with acute lymphocytic 
leukemia (ALL), disialoganglioside GD2-CAR T cell 
therapy to treat children with osteosarcoma and neuro-
blastoma and B cell maturation antigen (BCMA)-CAR 
T cells to treat adults with multiple myeloma. A recent 
clinical trial of CD19-CAR T cell therapy revealed a 70% 
clinical complete response rate among twenty pediatric 
B-Cell ALL patients. Grade 4 cytokine release syndrome 
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occurred in 14% of patients but all toxicities were revers-
ible and prolonged B-cell aplasia did not occur [120]. 
Although CD19-CAR T cells therapy has been successful, 
some products fail to expand in culture.
CAR T cells are manufactured from autologous periph-
eral blood mononuclear cell (PBMC) concentrates which 
are enriched for lymphocytes prior to initiating the T 
cell culture and gene transfer. Potential causes for T cell 
expansion failure included, poor quality T cells (due to 
prior chemotherapy, underlying disease, or biological 
variability) and poor quality of the apheresis product 
(due to inhibition by contaminating cells). A review of 43 
CD19-and 11 GD2-CAR T cell manufacturing records at 
one academic center found that for CD19-CAR T cells 
the yield of transduced cells was highly variable and 4 out 
of 28 CD19-CAR T cells products failed to meet trans-
duced T cell dose criteria (1 or 3  ×  106 transduced T 
cells/kg) [121]. Further investigation showed that large 
quantities of monocytes and granulocytes in PBMC con-
centrates were associated with poor CD19-CAR T cell 
yields. In addition, although the CD19- and GD2-CAR 
T cell manufacturing methods were similar, the yield 
of GD2-CAR T cells was much lower than the yield of 
CD19-CAR T cells and the proportion of monocytes in 
the PBMC concentrates used to manufacture GD2-CAR 
T cells was much greater that of PBMCs used to manu-
facture CD19-CAR T cells. More rigorous monocyte 
depletion of the PBMC concentrates improved both 
CD19- and GD2-CAR T cell yields especially those for 
GD2-CAR T cells.
These results suggest that some autologous PBMC con-
centrates collected from patients with ALL, sarcoma or 
neuroblastoma contain large quantities of monocytic and 
granulocytic myeloid derived suppressor cells that inhibit 
T cell expansion. Furthermore, aggressive depletion of 
PBMCs of monocytes and granulocytes improves T cell 
expansion.
Tumor microenvironment and biomarkers
Biomarkers can help with clinical decisions making for 
example predictive biomarkers to select patients who 
have a high likelihood of response to immunotherapy 
drugs. Other categories of biomarkers can serve dif-
ferent role in immune oncology (IO) as: (i) biomarkers 
before diagnosis that can be used for risk assessment and 
screening; (ii) at diagnosis biomarkers can assist with 
staging, grading, and therapy selection; and (iii) biomark-
ers also can be used to select additional therapy or for 
rational design of combination therapies or (iv) monitor 
for recurrent disease [122].
Immuno-therapeutic drug development now requires 
novel biomarker approaches considering the increas-
ing number of immunotherapy agents available for the 
treatment of advanced cancers and the percentage of 
patients not responding to immune checkpoint inhibi-
tors. Drug-specific predictive biomarkers would improve, 
at baseline for patient selection, benefit/risk and ulti-
mately effectiveness. Also, biomarkers guiding biology-
based combinations as well as optimal dose-schedule are 
still an unmet need.
Sources of inter-patient variability in IO include host 
germline polymorphisms in immune-regulatory genes, 
somatic alterations in tumor cells and environmental fac-
tors. Due to the complexity of the immune response and 
tumor biology it is unlikely that a predictive biomarker 
based on a single analyte will be very informative. Inte-
grated model measuring different parameters including 
host, cancer and microbiota would be needed to predict 
with high accuracy which patient will benefit from which 
approach, single agent or combination.
Molecular barcoding is a proprietary (Nanostring) tech-
nology platform based on a single molecule fluorescent 
barcoding that allows for direct, digital, multiplexed meas-
urements of gene expression from low amount of RNA 
without need for amplification with high precision and 
sensitivity (<1 copy per cell). It also has been optimized 
for formalin fixed paraffin embedded (FFPE) tissues/
biopsies. Measurements are performed by the nCounter 
analysis instrument using ad hoc software that provides 
automatic quality control (QC), normalization and dif-
ferent visualization tools. Application of this technology 
to immune-oncology has been already demonstrated as 
(PAM50) gene signature panel showed prognostic value in 
breast cancer and received clearance by FDA under 510(k) 
regulation. Pancancer immune profiling panel provides a 
multiplexed gene expression probes designed to quanti-
tate770 genes which fall under 4 categories:
  • 24 different immune cell types in PBMC or tissue
  • immunologic functions
  • tumor specific antigens such as CT antigens
  • housekeeping genes to facilitate sample to sample nor-
malization
Nanostring platform has been used to study the rela-
tionship between immune gene signatures and clini-
cal response to PD-1 blockade with pembrolizumab in 
patients with advanced solid tumors [123, 124]. Impor-
tantly those signatures have shown to be tumor type 
independent and to have higher negative predictive value 
(NPV) than immunohistochemistry (IHC)-based PD-L1 
measurements. Next generation of biomarkers will need 
to measure and integrate the complexity of host, tumor 
and environment which will likely require measurement 
of different molecular entities i.e., multi-omics meas-
urement of DNA, RNA, proteins, simultaneously (“3 D 
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biology”) in the same sample (maximizing the amount 
and type of information obtained per sample) and same 
units.
Two broad categories of tumor escape based on cellu-
lar and molecular characteristics of the tumor microenvi-
ronment have been recently suggested. One major subset 
shows a T cell-inflamed phenotype consisting of infiltrat-
ing T cells, a broad chemokine profile and a type I inter-
feron signature indicative of innate immune activation. 
These tumors appear to resist immune attack through the 
dominant inhibitory effects of immune system-suppres-
sive pathways. Most immunotherapy responders includ-
ing those treated with anti-PD1 have this phenotype. The 
other major phenotype lacks this T cell-inflamed pheno-
type and appears to resist immune attack through immune 
system exclusion or ignorance. These two major pheno-
types of tumor microenvironment may require distinct 
immunotherapeutic interventions for maximal therapeutic 
effect [125]. If checkpoint blockade is preferentially active 
in T cell-inflamed tumors, then what molecular mecha-
nisms explain the non-T cell-inflamed tumor microenvi-
ronment? Three major hypotheses have been proposed: (1) 
somatic differences at the level of tumor cells (as distinct 
oncogene pathways activated in different patients or muta-
tional landscape and antigenic repertoire), (2) germline 
genetic differences at the level of the host (polymorphisms 
in immune regulatory genes), or (3) environmental differ-
ences (as commensal microbiota or immunologic/patho-
gen exposure history of patients).
In order to evaluate the mutational landscape and 
antigenic repertoire, malignant melanoma samples from 
TCGA were segregated based on T cell-inflamed gene 
signature. Expression of differentiation antigens and 
cancer-germline antigens was found to be comparable in 
T cell signature-high versus-low patients. Similarly, the 
overall mutational load (non-synonymous mutations) is 
comparable in T cell signature-high versus -low samples. 
Also, T cell signature-high and -low patients have equal 
patterns of predicted HLA-A0201 binding peptides. On 
the other hand, a minimal representation of so-called 
“tetrapeptide” sequences were observed in T cell signa-
ture-high versus -low tumors.
The second unanswered questions is, if overall anti-
gen density is just as high in non-T cell-inflamed tumors, 
what is molecular explanation for absence of immune 
infiltrate [126]? A model of how melanoma-intrinsic 
β-catenin activation prevents host anti-tumor immune 
response has been proposed. Molecular analysis of 
human metastatic melanoma samples revealed a corre-
lation between activation of the WNT/β-catenin sign-
aling pathway and absence of a T-cell gene expression 
signature. The mechanism by which tumor-intrinsic 
active β-catenin signaling results in T-cell exclusion 
and resistance to anti-PD-L1/anti-CTLA-4 monoclonal 
antibody therapy was identified. Specific oncogenic sig-
nals, therefore, can mediate cancer immune evasion and 
resistance to immunotherapies, pointing to new candi-
date targets for immune potentiation [27].
The importance of commensal bacteria in explaining 
the different T cell-inflamed versus non-inflamed tumor 
microenvironments is based on their ability to shape 
systemic immunity. Jackson (JAX) and Taconic (TAC) 
mice exhibit robust versus weak anti-tumor immune 
responses and accumulation of intratumoral T cells. The 
difference between TAC and JAX mice was transferrable 
by co-housing or fecal transplant. The administration of 
JAX feces led to significantly improved tumor control 
and increased frequency of circulating antigen-specific 
T cells. The reciprocal transfer had little effect, consist-
ent with cohousing experiments. Finally, the abundance 
of Bifidobacterium spp. correlated with antigen-specific 
T cell responses. Oral administration of Bifidobacterium 
mix to tumor-bearing TAC recipients improved tumor-
specific immunity and response to αPD-L1 mAb. It is 
possible to conclude that T cell-inflamed tumor micro-
environment may serve as a predictive biomarker for 
response to immunotherapies and the lack of the T cell-
inflamed tumor microenvironment phenotype does not 
appear to be due to lack of antigens [127].
Mechanisms of PD-L1 expression may be either innate 
or adaptive, and the relative contribution of each mecha-
nism varies by tumor type and even within tumor types. 
In melanoma, the adaptive resistance mechanism pre-
dominates [128]. PD-L1 mediated adaptive immune 
resistance may be described with T-cells recognizing 
tumor antigens and, as they are activated, they express 
PD-1, and secrete IFN-gamma as a part of their cytotoxic 
anti-tumor response, leading to PD-L1 upregulation on 
tumor cells and associated immune cells. PD-L1 expres-
sion in this setting can thus be thought of as reflecting an 
ongoing immune reaction against tumor, and as such, its 
expression may be used to predict responses to anti-PD-
1-PD-L1 therapies [129, 130]. In tumors with constitutive 
PD-L1 expression, the predictive value of PD-L1 may be 
improved by adding an additional parameter such as infil-
trating CD8+ T-cells or an IFN-gamma gene signature.
In addition, to the different mechanisms underlying 
PD-L1 expression, some of the variation reported in the 
predictive value of PD-L1 as a biomarker may be attribut-
able to the different immunohistochemical (IHC) assays 
used for detection. The Blueprint Project is currently 
underway to characterize potential differences between 
the marketed diagnostic assays using the 28–8, 22C3, 
SP263, and SP142 monoclonal antibodies. When these 
four antibodies were compared in a laboratory derived 
test (rather than the marketed diagnostic assays), strong 
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correlations were seen in levels of PD-L1 detection in 
melanoma samples. Most of the observed variation was 
attributable to geographic heterogeneity between dif-
ferent tumor sections as opposed to antibody perfor-
mance. Next steps will likely focus on the reconciliation 
of the different marketed diagnostic assays amongst each 
other and with the standardization of evolving laboratory 
derived tests.
Other single markers have been nominated as predic-
tors of response to anti-PD-1/PD-L1 therapies, including 
CD8 density and mutational load. The TCGA dataset was 
used to explore the relationship between PD-L1, a cyto-
toxic gene signature (CYT), mutational load and survival 
in patients with metastatic melanoma. Increasing values 
for all three parameters were associated with improved 
survival. Notably, CYT and PD-L1 expression were highly 
interdependent, while mutational load was not directly 
related to the presence of an inflamed tumor phenotype. 
Future biomarker panels will undoubtedly incorporate 
multiple parameters assessed in surgical pathology speci-
mens, and studies focused on the integration and prior-
itization of distinct parameters beyond PD-L1 expression 
are currently underway.
The impact of the advances of the last few years on 
patients is tremendous. However, responses are heteroge-
neous and are not always durable. There is a critical need 
to better understand who will benefit from therapy, and 
this may best be accomplished through a deep molecu-
lar and immune analysis in samples from patients on 
therapy. In order to gain insight into response and resist-
ance to targeted therapy for melanoma, serial biopsies 
(for genomic analysis and immune profiling) were per-
formed in patients on BRAF inhibitors, pre-treatment, 
on-treatment, and at progression time points. Multiple 
molecular mechanisms of resistance have been identi-
fied. Oncogenic mutations contribute to tumor escape 
via multiple mechanisms. This is certainly the case in 
melanoma, where over half of patients have oncogenic 
mutations in the BRAF gene. Mutations in this gene lead 
to constitutive signaling though the MAPK pathway, with 
several deleterious effects, including uncontrolled prolif-
eration, resistance to apoptosis, increased angiogenesis, 
invasion and metastasis, as well as immune evasion. By 
blocking oncogenic BRAF it is possible to abrogate the 
effects, actually making tumors more immunogenic. 
Immune mechanisms of response and resistance to tar-
geted therapy were also identified, demonstrating that 
treatment with targeted therapy leads to a more favora-
ble tumor microenvironment with increased melanoma 
antigens and CD8+ T cells and decreased immunosup-
pressive cytokines and VEGF. There is also an increase in 
expression of the immunomodulatory molecule PD-L1, 
suggesting a possible immune mechanism of resistance 
to therapy. These favorable immune changes are not 
likely to be directly related to increased melanoma anti-
gen expression, but to overall changes in the microen-
vironment [131]. Investigating the antigen specificity 
of the infiltrating T cells, it resulted that treatment with 
targeted therapy results in a more clonal T cell response. 
Also, when the percent of pre-existing clones was plotted 
against treatment response, two groups clearly emerged: 
a group of patients with a low percentage of pre-existing 
clones who had a poor response to therapy and a group 
of patients with a high percentage of pre-existing clones 
who had a good response to therapy [132].
The hypothesis that combining targeted therapy and 
immune checkpoint blockade would enhance responses 
to therapy was then tested in a murine model and syn-
ergy was observed with delayed tumor outgrowth and 
prolonged survival when mice were treated with BRAF 
targeted therapy and PD-1 blockade, compared to either 
therapy alone [133].
Building on this data, the efforts were focused on bet-
ter understanding responses to immune checkpoint 
blockade. To do this, a deep tissue-based analysis in 
longitudinal tumor samples from patients on immune 
checkpoint blockade (this group initially received Ipili-
mumab and then went onto PD-1 blockade therapy at 
progression) was performed. Then a deep molecular and 
immune profiling of these tumors was carried out to 
investigate whether molecular and immune “signatures” 
exist in pre-treatment, and early on-treatment samples 
of patients receiving CTLA-4 and PD-1 blockade may 
be predictive of response. Results demonstrated that 
immune signatures in early on-treatment tumor biop-
sies on PD-1 blockade were highly predictive of response 
[134]. It is hence possible to conclude that insights into 
mechanisms of therapeutic resistance to therapy can be 
gained through a deep analysis of molecular and immune 
signatures in patients, and could lead to identification of 
better biomarkers and strategies to overcome therapeutic 
resistance.
The rationale of studying myeloid cells and tumor 
exosomes for assessing and targeting immunosuppres-
sion is based on the evidence that tumors, through the 
release of systemic factors into the blood stream, can 
influence bone marrow myelopoiesis and promote the 
release of altered myeloid cells that can then feed the 
cancer site with immunosuppressive effects. The major 
population involved in this process is represented by 
myeloid-derived suppressor cells (MDSC) expressing 
either granulocytic or monocytic markers in both mice 
and humans, and exerting a pleiotropic suppression on 
antitumor T cells and NK cells through complex path-
ways. MDSC infiltrate tumor site where they can dif-
ferentiate into tumor associated macrophages (TAM2) 
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and sustain chronic inflammation. The immunosuppres-
sive activity of monocytes from melanoma patients was 
investigated and CD14+ monocytes were found to exert 
immunosuppressive activity increased by 96  kDa heat 
shock protein (HSPPC-96)/GM-CSF vaccine, thus per-
mitting to identify a new subset of MDSC potentially 
expandable by the administration of GM-CSF—based 
vaccines in metastatic melanoma patients [135].
Several studies have shown that tumor exosomes 
deliver information not only between tumor cells but 
also to other cell types, including different immune cell 
components. Exosomes are endosomal-derived nan-
ovesicles released by most cells types, including tumor 
cells, and principally involved in intercellular communi-
cation in disease. There is increasing evidence that these 
extracellular vesicles (EVs), when released by malignant 
cells, may contribute to cancer progression by influenc-
ing different immune cell types, likely blunting specific T 
cell immunity and skewing innate immune cells toward a 
pro-tumorigenic phenotype. Because of this function and 
the ability to deliver molecular signals modulating neo-
angiogenesis and stroma remodeling, tumor exosomes 
are believed to play a role in tumor progression by estab-
lishing metastatic niche [136]. Exosomes are crucial 
mediators of autocrine and paracrine intercellular traf-
ficking of proteins and genetic material and thus are gain-
ing attention as diagnostic biomarkers and therapeutic 
tool in different diseases including cancer.
Exosomes might be also involved in the generation 
of MDSC and in the cell-independent miRNA biogen-
esis and in the promotion of tumorigenesis. However, 
the question whether there is any link between tumor 
exosomes and MDSC and whether exosomes have the 
ability to mediate immune suppression remains unan-
swered. Preliminary data demonstrating the existence of 
this cross-talk (V. Umansky, DKFZ, Heidelberg, unpub-
lished) showed that systemic injection of melanoma 
exosomes leads to MDSC induction in several immune 
sites including the bone marrow [137]. These data dem-
onstrate the important role of miRNA in the immune 
regulation and suggest that the transfer of miRNA in 
exosomes from tumor to the host cells in tumor micro-
environment is responsible for the changes in immuno-
suppressive phenotype. Melanoma cells with silenced 
miRNA, released exosomes that no longer carry this 
genetic material and, most importantly, no longer induce 
MDSC differentiation of normal monocytes. The evi-
dence also suggests the occurrence of this pathway in 
melanoma patients, including the expression of MDSC-
specific miRNA in circulating monocytes, tumor lesions, 
and plasma. Together with other soluble factors, tumor 
extracellular vescicles could be responsible for the MDSC 
expansion and activation of their immunosuppressive 
functions in a wide range of tumors. The possibility 
to identify and isolate cells that are the target of tumor 
miRNA will be crucial for the identification and analy-
sis of novel pathways in stromal cells that support tumor 
growth.
It is therefore possible that the melanoma lesions 
release larger vesicles that target CD14+ cells and are 
responsible for the increased frequency of MDSC. Also, 
as MDSC specific miRNAs are present at higher levels in 
plasma of melanoma patients, they can serve as a plasma 
surrogate of MDSC activity and a potential plasma bio-
marker of myeloid dysfunctions and as a target for immu-
nomodulation in melanoma patients. These data open 
new potential routes to the use of MDSC-specific miR-
NAs as biomarker and therapeutic target in clinical can-
cer setting.
The availability of immune prognostic factors will 
help to optimize adjuvant therapies in stage III meta-
static melanoma. More than 125 immune parameters 
were investigated by flow cytometry and on paired blood 
and tumor specimen in 39 stage III melanoma patients. 
Results demonstrated that T cell exhaustion markers 
correlate best with prognostic clinical parameters and 
there is a high correlation between immunophenotypic 
biomarkers in blood and tumor. High frequencies of 
CD45RA+ CD4+ and CD3− CD56— tumor-infiltrating 
lymphocytes appear to be independent prognostic factors 
of short progression-free survival (PFS). Also, regulatory 
Treg within tumor-infiltrating lymphocytes are indicative 
of dismal prognosis, specifically in BRAF mutated mela-
noma. High natural toxicity receptor NKG2D expres-
sion on CD8+ tumor-infiltrating lymphocytes, low level 
of Treg, and low PD-L1 expression on circulating T cells 
predicted prolonged overall survival in the multivariate 
Cox analysis model [138].
Chemokines are critical regulators of leukocyte traf-
ficking and immune functions. The expression pat-
terns of nine homing receptors (CCR/CXCR) in naive 
and memory CD4+ and CD8+ T lymphocytes in 57 
patients with metastatic melanoma (MM) with various 
metastatic sites were retrospectively analyzed to evalu-
ate whether T cell CCR/CXCR expression correlates with 
intratumoral accumulation, metastatic progression, and/
or overall survival (OS). Expression of homing receptor 
on lymphocytes strongly correlated with metastatic dis-
semination. Polyfunctional inflammatory cells such as 
CD8+  CCR6+  TEM and CD4+  CLA+  CCR10+  TEM 
that are TH2 cells present in blood are associated with 
bad prognosis in stage IV metastatic melanoma. Whereas 
CD8+  CCR9+  TN and CD4+  CXCR3+  TEM cells in 
blood are associated with more favorable prognosis in 
stage IV metastatic melanoma. Finally, in mice, CCR9/
CCL25 and CXCR3 play complementary roles in natural 
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immunosurveillance of cancer [139]. These data suggest 
that the interface between tumor and the host including 
activating pathways and tumor induced immunosuppres-
sive mechanisms have to be analyzed on individual basis. 
Preliminary results have shown that each tumor draining 
lymph node of MM demonstrated individual reactivity 
profile to 11 different biomarkers detected with specific 
mAb, thus setting the stage for precision immunotherapy.
The role of intestinal dysbiosis should also be consid-
ered in response to immunotherapy in melanoma. The 
antitumor effects of CTLA-4 blockade depends on dis-
tinct Bacteroides species of gut microbiota. Link between 
CTLA-4 blockade, intestinal damage, dysbiosis, anti-
microbial immune responses and anti-cancer immunity 
and rejection have been demonstrated [140]. Enterotyp-
ing of metastatic melanoma patients might therefore help 
to optimize responses to ipilimumab therapy. A cluster-
ing algorithm based on genus composition is currently 
under evaluation [140].
In 2014 the Society for Immunotherapy of Cancer 
(SITC) convened an Immune Biomarkers Task Force to 
review the state of art of existing assays and technolo-
gies, identify challenges for further success and provide 
recommendations for developing biomarkers for immu-
notherapy. The charge to one of the Working Group was 
to address pre-analytical and analytical as well as clini-
cal and regulatory aspects of the validation process as 
applied to biomarkers for cancer immunotherapy.
Biomarker assay validation process can be separated 
into several continuous steps; assessment of basic assay 
performance (analytical validation); characterization of 
the performance of the assay with regard to its intended 
use (clinical validation); and validation in clinical trials 
that ensures that the assay performs robustly according 
to predefined specifications (fit-for-purpose) and facili-
tates the establishment of definitive acceptance criteria 
for clinical use (validation of clinical utility). A typical 
analytical validation plan involves several steps in which 
the assay must be optimized for multiple parameters: 
(i) sample-related (pre-analytic parameters), (ii) assay-
related (analytical parameters); and (iii) data-related 
(post-analytical parameters) [141].
An important step in biomarker validation is the eval-
uation of pre-analytical factors that may affect assay 
performance due to specimen-related variability. For 
immunotherapies, there may be a need to monitor 
ex vivo immune responses in phenotypical or functional 
assays, which require high-quality samples to ensure reli-
able analytic output. To ensure that optimal pre-analytic 
processing regimens are followed, standard operating 
procedures (SOPs) for controlling specific biomarker 
development steps are essential.
Preanalytical processing of blood and analyte stability 
can be affected by the sample collection process includ-
ing anticoagulants used for blood draws, freezing/thaw-
ing, time between collection and testing, and storage 
conditions before processing. Tissue based biomarkers 
can be measured on freshly frozen (FF) tumor samples 
or formalin fixed paraffin embedded (FFPE) tissue. FFPE 
tissue blocks are often available as archival materials as 
part of bio-banked samples for conventional immuno-
histochemistry (IHC). IHC is a multi-step diagnostic 
process that requires standardized conditions for tissue 
collection, fixation and processing, preparation of the 
IHC slide, and interpretation of the staining results. IHC 
based assays remain an important test as companion 
diagnostics (CDx) to assess antigen expression on diag-
nostic or surgical specimens for selecting patients and 
predicting patient-response to specific targeted therapy 
(e.g., HER2 expression for Herceptin or mutated BRAF 
for BRAF-inhibitor treatment), and more recently PD-L1 
as companion diagnostic for pembrolizumab treatment 
of NSCLC patients [142].
General guidelines, including analyte stability and labo-
ratory quality control, for performing analysis of tissue-
based molecular biomarkers have been published [143].
Next generation sequencing (NGS) tests for tumor 
mutation analysis, similar to other complex molecular 
diagnostic tests, should demonstrate adequate analytical 
and clinical performance [144].
It should follow SOPs that specifically address materials 
and procedures including patient’s sample type, method 
of DNA extraction, as well as technical metrics for DNA 
quantification and quality, which can negatively impact 
on sensitivity and reproducibility of the assay [145].
Analytical Validation involves confirming that the assay 
used for the biomarker measurement has established: (i) 
Accuracy, (ii) Precision, (iii) Analytical sensitivity, (iv) 
Analytical specificity, (v) Reportable range of test results 
for the test system, (vi) Reference intervals (normal val-
ues) with controls and calibrators, (vii) Harmonized 
analytical performance if the assay is to be performed in 
multiple laboratories, (viii) Establishment of appropriate 
quality control measures. Depending on the particular 
category an assay can require distinct type of validation. 
Definite quantitative assays make use of calibrators and 
a regression model to calculate absolute quantitative val-
ues for unknown samples. The reference standard must 
be well defined and should be a representative of the bio-
marker. This type of assay can be accurate and precise. In 
relative-quantitative assays, reference calibrators can be 
used; however, because standards are not fully represent-
ative of the biomarker, assay precision can be validated, 
while the accuracy of the assay can only be estimated. 
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Validation and maintaining reproducibility of multipara-
metric assays is much more challenging considering the 
number of analytic variables associated with high content 
assays (NanoString, single cell networ profiling (SCNP), 
mutational load, TCR sequencing). The capacity of high 
throughput platforms, such as NanoString or flow based 
analysis SCNP, enable multi-dimensional analysis of the 
immune system. Instead of detecting a single or limited 
number of molecular targets, assays are able to detect 
tens to hundreds of distinct molecular features simulta-
neously [146].
The post-analytical phase of biomarker evaluations 
involves data interpretation of the assay results. Dichoto-
mous variables are relatively straightforward to incorpo-
rate into calculations of data sensitivity and specificity. 
However, most variables in measurement of immune 
response are continuous, resulting in variability with 
respect to analytical performance criteria and clinical rel-
evance of the assay, e.g., cut-off points for clinical deci-
sion making. Essentially, a cut-off for classifying a sample 
as positive or negative needs to be determined empiri-
cally by correlating results with clinical outcomes in a 
clinical trial exploring efficacy of a drug.
As high throughput methods became widely avail-
able there is a need for computational methodologies 
for interpretation of the complex data for biological and 
clinical implications. Algorithms to develop multimodal 
signatures integrating various types of molecular tumor 
data (i.e., genomics, protein expression, functional etc.) 
with TME factors that reflect the complex biomarker 
information require the development of multifactorial 
classifiers/algorithms.
The final stage in the development of a biomarker pre-
dictive of clinical outcome or response is the assessment 
of its clinical validity and utility through the application 
of the analytically validated assay within a clinical trial, 
with multiple design options depending on the intended 
use of the test and availability of specimens from previ-
ous clinical trials.
Clinical validity relates to the observation that the pre-
dictive assay reliably divides the patient population(s) 
of interest into distinct groups with different expected 
outcomes to a specific treatment. The criteria for vali-
dation are defined by the nature of the question that the 
biomarker is intended to address (i.e., fit-for-purpose). 
A predictive biomarker needs to demonstrate the asso-
ciation with a specific clinical endpoint (e.g., survival or 
tumor response) in pre-treatment samples from patients 
that have been treated or exposed to a uniform treatment 
intervention. For example, the programmed cell death-1 
protein ligand (PD-L1) immunohistochemistry (IHC 
22C3 pharmDx) test was approved as a CDx to pembroli-
zumab (anti-PD-1 mAb inhibitor from Merck) as a single 
agent in second-line non-small cell lung cancer (NSCLC) 
[142].
There are multiple steps for biomarker clinical valida-
tion that encompass important elements of clinical study 
design and data analysis, including statistical assessments 
that rely on samples collected from prospective clinical 
trials or from archived samples that are well annotated 
with relevant clinical information. Clinical validation i.e., 
assessment of the test’s correlation with clinical outcome 
and the amount of improvement in patient outcomes its 
adoption would entail. The clinical sensitivity and speci-
ficity of the assay must be demonstrated through robust 
receiver operating characteristics (ROC) curves that 
provide support for the cut points, established using 
appropriate statistical analysis to identify responders 
versus non-responders. Statistically, several approaches 
can be applied for clinical validation of an assay. Internal 
validation can be achieved by using a study population 
that reflects the target population in which the test will 
be used. The study population is divided into two inde-
pendent groups of specimens. One of these groups is the 
“training set”, i.e., the set of samples used to identify and 
characterize the “biomarker” (if single analyte) or to build 
a mathematical model or algorithm (in case of multi-var-
iate assays). The second sample group is “the validation 
set” that is used to test whether the external validity of 
the biomarker/model is maintained in a sample cohort—
independent from the training set.
There are three basic phase III design options that are 
frequently considered for assessing the ability of a bio-
marker to identify a subgroup of patients who will ben-
efit from (or will not benefit from, and therefore should 
be avoiding) a new therapy. These are classified broadly 
into three categories: (i) The enrichment design; (ii) The 
stratified design; and (iii) The strategy design.
A clinical trial to evaluate the clinical utility of an omics 
test should be conducted with the same rigor as a clini-
cal trial to evaluate a new therapy. This includes develop-
ment of a formal protocol clearly detailing pre-specified 
hypotheses, study methods, and a statistical analysis 
plan. In some instances, a candidate predictive test for 
an existing therapy can be evaluated efficiently by using 
a prospective-retrospective design, in which the test is 
applied to archived specimens from a completed trial and 
the results are compared with outcome data that have 
already been collected. The “retrospective” aspect of this 
design requires that the assay can in fact be performed 
reliably on stored specimens [147].
In conclusion, immunotherapies have emerged as the 
most promising class of drugs to treat patients with can-
cer with diverse tumor types, however many patients 
do not respond to these therapies. Therefore, determin-
ing which patients derive clinical benefit from immune 
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checkpoint agents remains an important clinical question 
and efforts to identify predictive markers of response are 
ongoing. The analytical and clinical validation of pre-
dictive biomarkers require appropriate clinical studies 
in which the evaluation of the clinical utility of the bio-
marker is a pre-specified endpoint of the study. A vari-
ety of study designs have been proposed for this purpose. 
Although, the randomized biomarker stratified design 
provides the most rigorous assessment of biomarker 
clinical utility, other study designs might be acceptable 
depending on the clinical context.
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